###begin article-title 0
###xml 103 104 103 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn1">*</xref>
###xml 104 104 104 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn2"/>
Identification and Functional Characterization of an N-terminal Oligomerization Domain for Polycystin-2*
###end article-title 0
###begin p 1
Supported by a PhD studentship from the Sheffield Area Kidney Association.
###end p 1
###begin p 2
###xml 312 333 312 333 <email xmlns:xlink="http://www.w3.org/1999/xlink">a.ong@sheffield.ac.uk</email>
 To whom correspondence should be addressed: Kidney Genetics Group, Academic Unit of Nephrology, The Henry Wellcome Laboratories for Medical Research, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Rd., Sheffield S10 2RX, UK. Tel.: 44-114-271-3402; Fax: 44-114-271-1711; E-mail: a.ong@sheffield.ac.uk.
###end p 2
###begin p 3
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice
###end p 3
###begin p 4
 applies to Author Choice Articles
###end p 4
###begin p 5
###xml 138 142 138 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD1</italic>
###xml 152 156 152 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 759 764 <span type="species:ncbi:4932">yeast</span>
###xml 1002 1011 <span type="species:ncbi:7955">zebrafish</span>
Autosomal dominant polycystic kidney disease (ADPKD), the most common inherited cause of kidney failure, is caused by mutations in either PKD1 (85%) or PKD2 (15%). The PKD2 protein, polycystin-2 (PC2 or TRPP2), is a member of the transient receptor potential (TRP) superfamily and functions as a non-selective calcium channel. PC2 has been found to form oligomers in native tissues suggesting that it may form functional homo- or heterotetramers with other subunits, similar to other TRP channels. Our experiments unexpectedly revealed that PC2 mutant proteins lacking the known C-terminal dimerization domain were still able to form oligomers and co-immunoprecipitate full-length PC2, implying the possible existence of a proximal dimerization domain. Using yeast two-hybrid and biochemical assays, we have mapped an alternative dimerization domain to the N terminus of PC2 (NT2-1-223, L224X). Functional characterization of this domain demonstrated that it was sufficient to induce cyst formation in zebrafish embryos and inhibit PC2 surface currents in mIMCD3 cells probably by a dominant-negative mechanism. In summary, we propose a model for PC2 assembly as a functional tetramer which depends on both C- and N-terminal dimerization domains. These results have significant implications for our understanding of PC2 function and disease pathogenesis in ADPKD and provide a new strategy for studying PC2 function.
###end p 5
###begin p 6
###xml 49 78 49 78 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">National Institutes of Health</grant-sponsor>
###xml 86 98 86 98 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">R21-DK069604</grant-num>
###xml 100 112 100 112 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">RO1-DK078209</grant-num>
###xml 129 140 129 140 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">R01-DK59599</grant-num>
###xml 198 212 198 212 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">PKD Foundation</grant-sponsor>
###xml 214 219 214 219 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">69a2r</grant-num>
###xml 224 230 224 230 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">119a2r</grant-num>
###xml 233 291 233 291 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">John S. Gammill Endowed Chair in Polycystic Kidney Disease</grant-sponsor>
###xml 293 313 293 313 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Research Councils UK</grant-sponsor>
###xml 315 323 315 323 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">RA108836</grant-num>
###xml 348 362 348 362 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Wellcome Trust</grant-sponsor>
###xml 364 372 364 372 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">GR071201</grant-num>
###xml 533 546 533 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">advertisement</italic>
This work was supported, in whole or in part, by National Institutes of Health Grants R21-DK069604, RO1-DK078209 (to T. O.), and R01-DK59599 (to L. T.). This work was also funded by grants from the PKD Foundation (69a2r and 119a2r), John S. Gammill Endowed Chair in Polycystic Kidney Disease, Research Councils UK (RA108836) (to A. J. S.), and the Wellcome Trust (GR071201) (to A. C. M. O.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 6
###begin p 7
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice-Final version full access.
###end p 7
###begin p 8
###xml 53 54 53 54 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn4">3</xref>
###xml 152 156 152 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD1</italic>
###xml 160 164 160 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 166 167 166 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref1">1</xref>
###xml 644 645 632 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 81 86 <span type="species:ncbi:9606">human</span>
###xml 209 217 <span type="species:ncbi:9606">patients</span>
###xml 326 334 <span type="species:ncbi:405018">cardinal</span>
Autosomal dominant polycystic kidney disease (ADPKD),3 the most common inherited human renal disease, has been shown to result from mutations in either PKD1 or PKD2 (1). ADPKD accounts for approximately10% of patients on renal replacement therapy and is therefore an important cause of end-stage renal failure world-wide. The cardinal feature of the ADPKD kidney is the presence of multiple fluid-filled cysts. However, cysts also arise in other epithelial structures such as the liver and pancreas. A number of non-cystic manifestations such as cardiac valve abnormalities, diverticular disease, and intracranial aneurysms have been reported (2).
###end p 8
###begin p 9
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 160 161 160 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref3">3</xref>
###xml 224 226 224 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 451 452 451 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref4">4</xref>
###xml 454 455 454 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 520 522 520 522 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 549 550 549 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 796 797 796 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref7">7</xref>
###xml 798 799 798 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 959 961 959 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref10">10</xref>
###xml 963 965 963 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 1058 1060 1058 1060 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1094 1096 1094 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 41 49 <span type="species:ncbi:9606">patients</span>
Mutations in PKD2 account for 15% of all patients with ADPKD. The PKD2 protein, polycystin-2 (PC2), is a Type II membrane protein of 968 amino acids in length (3). PC2 has the properties of a high-conductance nonselective Ca2+-permeable cation channel. Because of significant homology, PC2 (or TRPP2) has been included in the TRP (transient receptor potential) superfamily of channels, which broadly function as cellular sensors for multiple stimuli (4, 5). There is evidence that PC2 may transduce a mechanosensitive Ca2+ current in primary cilia (6) although it is unclear whether the mechanosensor is PC1, PC2, or another protein. However, it has also been reported that PC2 can function downstream of G protein-coupled receptor and/or receptor-tyrosine kinase activation at the cell surface (7-9). The basolateral localization of PC2 in kidney tubules and cells has implicated a possible role in cell-cell or cell-matrix adhesion in association with PC1 (10, 11). Finally, it has been reported that PC2 can function as an endoplasmic reticulum-located Ca2+ release channel in some systems (12).
###end p 9
###begin p 10
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref10">10</xref>
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 365 366 365 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 368 369 368 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 593 594 593 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 754 755 754 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 757 759 757 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref15">15</xref>
###xml 600 605 <span type="species:ncbi:4932">yeast</span>
Previously we demonstrated that PC2 can exist as PC1-PC2 heterodimers as well as PC2 homodimers in native tissues (10). Interactions between PC1 and PC2 may regulate their trafficking and there is evidence for reciprocal activation or inhibition of activity in different experimental systems (13, 14). PC2 may also heterodimerize with TRPC1 through its C terminus (5, 9). PC2-TRPC1 heteromultimers have been shown to possess distinct channel properties from PC1-PC2 heterodimers, being activated in response to G protein-coupled receptor activation in the kidney epithelial cell line, mIMCD3 (9). In yeast two-hybrid assays, PC2 can homodimerize via a C-terminal domain, which is distinct from heterodimerization sequences for PC1 or TRPC1 interactions (5, 15). In this report, we describe the identification and functional characterization of a second dimerization domain for PC2 within the N terminus and propose a likely homotetrameric model for PC2 based on C- and N-terminal interactions.
###end p 10
###begin title 11
EXPERIMENTAL PROCEDURES
###end title 11
###begin p 12
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Materials</italic>
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref16">16</xref>
###xml 282 284 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 75 80 <span type="species:ncbi:4932">Yeast</span>
Materials-All chemicals were purchased from Sigma unless otherwise stated. Yeast vectors pGBAD-B and pACT2-B were obtained from D. Markie (University of Otago, NZ) (16). The plasmids LDR and CF used for the FKBP-FRB dimerization system were gifts of T. Meyer (Stanford University) (17).
###end p 12
###begin p 13
###xml 0 27 0 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Generation of PKD2 Plasmids</italic>
###xml 57 61 57 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref18">18</xref>
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
###xml 265 269 265 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 392 394 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
###xml 420 424 420 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 618 622 618 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 751 753 751 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
###xml 984 988 984 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
Generation of PKD2 Plasmids-Unless otherwise stated, the PKD2 plasmids used in this work have been previously reported (18, 19). N-terminal HA-tagged full-length and mutant (L703X) PKD2 constructs were created by replacing an XbaI and SacII fragment of a wild-type PKD2 plasmid (gift of S Somlo, Yale University) with the same fragment excised from the previously described HA-L224X plasmid (19). A C-terminal HA-tagged PKD2 mutant construct, R742X, was generated by PCR using the wild-type PKD2Pk plasmid as a template including the HA epitope tag sequence and in-frame stop codon in the reverse primer. The missense PKD2 mutation, D511V, was created by site-directed mutagenesis in the PKD2Pk plasmid template using a previously published protocol (19). The N-terminal Myc-tagged L224X plasmid was generated by PCR and subcloned into the XbaI and HindIII sites of pcDNA3.1 (-). The plasmids CFP-PKD2-(1-177) and CFP-PKD2-(1-223) were generated by fusing the N-terminal sequences of PKD2 in-frame with the CFP and FKBP cassette in the vector, CF.
###end p 13
###begin p 14
###xml 0 38 0 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Immunoblotting and Immunoprecipitation</italic>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref10">10</xref>
###xml 551 553 551 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref18">18</xref>
###xml 144 150 <span type="species:ncbi:9913">bovine</span>
###xml 510 515 <span type="species:ncbi:9606">human</span>
Immunoblotting and Immunoprecipitation-HEK-293 and mIMCD3 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Transient transfection was carried out on cells cultured to 90% confluency using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Immunoblotting and immunoprecipitation (IP) was performed as previously described using epitope-specific antibodies (10). The PKD2 antibody, p30, generated to the C-terminal 258 amino acids of human PC2, has been previously reported (18).
###end p 14
###begin p 15
###xml 0 23 0 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Yeast Two-hybrid Assays</italic>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
###xml 990 991 984 985 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1156 1157 1150 1151 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1541 1550 1535 1544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e. PKD2</italic>
###xml 1561 1565 1555 1559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD1</italic>
###xml 0 5 <span type="species:ncbi:4932">Yeast</span>
###xml 24 29 <span type="species:ncbi:4932">Yeast</span>
###xml 70 75 <span type="species:ncbi:4932">yeast</span>
###xml 288 293 <span type="species:ncbi:9606">human</span>
###xml 328 333 <span type="species:ncbi:4932">yeast</span>
###xml 1328 1332 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
Yeast Two-hybrid Assays-Yeast two-hybrid assays were performed in the yeast strain AH109 containing ADE2, HIS3, and LacZ reporter genes under the control of the GAL4 upstream activating sequences (UAS) by co-transforming bait and prey constructs of the entire intracellular N terminus of human PC2 (NT2) or its truncations into yeast cells using a published protocol (20). Full-length NT2-(1-223) was subcloned into bait (BD) vector pGBKT7 and prey (AD) vector pGADT7 (Clontech), respectively, by PCR and DNA ligation. Similarly, the following NT2 truncations, NT2-(1-207), NT2-(1-198), NT2-(1-177), NT2-(1-117), NT2-(1-61), and NT2-(178-223) were constructed in both bait and prey vectors. After incubation at 30 degreesC for 3-4 days, positive co-transformants (containing both bait and prey plasmids) were picked from selective medium S.D./-LT (lacking tryptophan and leucine) and restreaked onto selective media S.D./-LTH (lacking tryptophan, leucine, and histidine), S.D./-LTH with 2 mm 3-amino-1,2,4-triazole (3-AT), and S.D./-LTAH (lacking tryptophan, leucine, histidine, and adenine), respectively, to activate the reporter genes HIS3 and ADE2. 2 mm 3-AT was used in the selective medium to suppress minor autoactivation of NT2-(1-198) and NT2-(1-177) in the pGBKT7 vector. The constructs pGBKT7-53 (p53) and pGBADT7-T (SV40 T-antigen) were used as a pair of positive controls. Truncations of the PC2 C terminus (CT2) and PC1 C terminus (CT1), which mimic two naturally occurring mutants lacking their respective interaction domains i.e. PKD2-R742X and PKD1-R4227X, respectively, were generated as a pair of negative controls: pGBAD-B-CT1 (4107-4227) and pACT2-B-CT2 (680-742). At least three individual colonies were chosen from each plate to quantify growth.
###end p 15
###begin p 16
###xml 0 17 0 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Live Cell Imaging</italic>
###xml 318 319 317 318 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 964 965 959 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 991 993 986 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
Live Cell Imaging-IMCD3 and HEK-293 cells were transiently transfected using Lipofectamine 2000 (Invitrogen) with the following cDNAs: CFP-FKBP-L223 (CF-PKD2-223), CFP-FKBP-L177 (CF-PKD2-177), and Lyn11-FRB (LDR). Translocation of the fusion proteins to the cell surface was induced 24 h later by the addition of 10 mum rapamycin (Calbiochem) to the culture media. In some experiments, co-expression of a surface-localized YFP fusion protein (C1 domain of PKC-gamma1, YFP-C1 (PKC)) was used to outline the plasma membrane. Live cell measurements were performed on an Olympus Imaging Systems inverted IX-71 microscope with a CFP and YFP filter set to capture cellular fluorescence images with a CCD camera (Hamamatsu), driven by Simple PCI software (C Imaging Systems). Fluorescence images of cells were taken every5sat room temperature. Changes in the mean fluorescence intensity over a given region of the cytosol and nucleus were quantified in individual cells (n = 6) using ImageJ (NIH) (21).
###end p 16
###begin p 17
###xml 0 17 0 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Electrophysiology</italic>
###xml 1304 1305 1292 1293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1395 1396 1383 1384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1441 1442 1429 1430 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1552 1553 1540 1541 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1571 1572 1559 1560 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1592 1593 1580 1581 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Electrophysiology-The whole cell voltage-clamp configuration was used in the perforated mode to measure transmembrane currents in single cells. Briefly, patch-clamp recordings were obtained from single cells at 37 degreesC using a Warner PC-505B amplifier (Warner Instrument Corp., Hamden, CT) and pClamp 8 software (Axon Instrument, Foster City, CA). Glass pipettes (plain, Fisher Scientific) with resistances of 5-8 MOmega were prepared with a pipette puller and polisher (PP-830 and MF-830, respectively, Narishige, Tokyo, Japan). After the whole cell configuration was achieved, cell capacitance and series resistance were compensated before each recording period. Current measurements in time course experiments were made by applying a 100-ms pulse from a holding potential -60 mV to -100 every 10 s for 5 min. Current amplitude was extracted at -100 mV and plotted as function of time (min). I-V curves were derived from a voltage step protocol as follows: from a holding potential of -60 mV, voltage steps were applied from -100 to 100 mV in 20-mV increments with 200 ms duration at 3-s intervals. Current traces were filtered at 1 kHz and analyzed off-line with pClamp 8. Statistical analysis was employed with the SigmaStat (Chicago, IL) software. Data were reported as means +/- S.E. Student's t test was used for comparisons between groups. Differences were considered significant at p < 0.05. The pipette solution contained (in mm): 0.3 Amphotericin B, 110 potassium aspartate, 30 KCl, and 5 HEPES, pH 7.2. The bath solution contained (in mm): 130 KCl, 1 MgCl2, 10 HEPES, 0.1 CaCl2, and 5 glucose (pH 7.4).
###end p 17
###begin p 18
###xml 0 21 0 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Zebrafish Experiments</italic>
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 278 282 278 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pkd2</italic>
###xml 338 342 338 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pkd2</italic>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 418 419 418 419 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 421 429 421 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
###xml 469 473 469 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 691 693 691 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
###xml 0 9 <span type="species:ncbi:7955">Zebrafish</span>
###xml 32 41 <span type="species:ncbi:7955">zebrafish</span>
###xml 328 337 <span type="species:ncbi:7955">zebrafish</span>
###xml 463 468 <span type="species:ncbi:9606">human</span>
Zebrafish Experiments-Wild-type zebrafish AB strains were maintained and staged according to standard protocols (22). Embryos were treated with 0.003% 1-phenyl-2-thiourea (Sigma) in x0.5 E2 solution to reduce pigmentation. At the one-cell stage, embryos were microinjected with pkd2ATGMO or control MO (Gene Tools LLC) to block zebrafish pkd2 translation as described (23) at final MO concentrations estimated at 100 nm. In vitro-transcribed capped mRNA encoding human PKD2-L177, -L223, and D511V were synthesized using a mMessage mMachine T7 kit (Ambion), and 50 pg were injected or co-injected at the one-cell stage. Injection solution conditions have been described in a previous report (19).
###end p 18
###begin p 19
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RT-PCR</italic>
###xml 142 146 140 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 504 508 479 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 136 141 <span type="species:ncbi:9606">human</span>
###xml 181 190 <span type="species:ncbi:7955">zebrafish</span>
###xml 498 503 <span type="species:ncbi:9606">human</span>
RT-PCR-Total RNA was isolated from 48 hpf embryos by using the RNAqueous(R)-4PCR Kit (Ambion). Nested RT-PCR primers were designed from human PKD2 sequence to confirm expression in zebrafish embryos. RT-PCR was performed using the SuperScripttrade mark III One-Step RT-PCR System with Platinum(R) Taq High Fidelity (Invitrogen) followed by a second PCR using Phusiontrade mark High-Fidelity DNA Polymerase (New England BioLabs). Amplification of beta-actin was performed as a positive control. The human PKD2 primers used were: 148F1: GGCCTGGAGATCGAGATG, 332R1: ACCACCATTCCGCCTTCT, 149F2: GCCTGGAGATCGAGATGC, 320R2: CCTTCTTCCCCTTCCACCT. All procedures involving kits were performed according to the manufacturers' protocols.
###end p 19
###begin p 20
###xml 0 20 0 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Immunohistochemistry</italic>
###xml 338 340 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref24">24</xref>
###xml 27 36 <span type="species:ncbi:7955">zebrafish</span>
###xml 244 248 <span type="species:ncbi:9925">goat</span>
###xml 501 505 <span type="species:ncbi:9925">goat</span>
###xml 511 517 <span type="species:ncbi:9986">rabbit</span>
Immunohistochemistry-Whole zebrafish embryos were fixed in 100% MeOH at 4 degreesC overnight. After rehydration, embryos were washed in PBS plus 0.5% Triton X-100 and blocked in PBS-DTR (PBS plus 1% DMSO, and 0.5% Triton X-100) with 10% normal goat serum (NGS) at room temperature for 1 h. Anti-polycystin-2 (1:800; gift of I. Drummond) (24) was incubated in PBS-DTR 2% NGS for 4 degreesC overnight. Embryos were washed in PBTX (PBS/0.5% Triton X-100) for 2 h and then incubated in 1:1000 CY3-labeled goat anti-rabbit IgG (Jackson ImmunoResearch) in PBS-DTR 2X NGS at room temperature for 2 h. After rinsing the embryos in PBTX for 2 h, they were dehydrated, embedded in JB-4 (Polyscience), and sectioned at 10-mum thickness. Sections were stained with 1:1000 DAPI (KPL) solution for 3 min at room temperature, the slides rinsed once with PBS and then mounted with fluorescent mounting medium (KPL). Section images were taken using a Nikon E500 microscope and analyzed by the Spot v. 4.4 program.
###end p 20
###begin p 21
###xml 0 14 0 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Histochemistry</italic>
###xml 177 178 177 178 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 183 184 183 184 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 509 510 502 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn5">4</xref>
Histochemistry-48-days postfertilization (dpf) embryos were fixed in 1.5% glutaraldehyde (Electron Microscopy Sciences), 1% paraformaldehyde (Electron Microscopy Sciences), 70 mm NaPO4 pH 7.4, 3% sucrose at 4 degreesC overnight, dehydrated, embedded in glycolmethacrylate (JB4; Polyscience), and sectioned at 4-mum thickness using HM325 (Richard-Allan Scientific). Slides were stained with hematoxylin and eosin (BBC Biochemical) according to the protocol from Jennifer R. Panizzi and Lilianna Solnica-Krezel.4
###end p 21
###begin title 22
RESULTS
###end title 22
###begin p 23
###xml 0 49 0 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Evidence for a Second Dimerization Domain in PKD2</italic>
###xml 99 103 99 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 269 275 269 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 450 452 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref25">25</xref>
###xml 583 584 583 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 605 607 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref26">26</xref>
###xml 650 652 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref10">10</xref>
###xml 667 671 667 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 808 809 808 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 802 809 802 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 1040 1044 1040 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 1164 1168 1164 1168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 1237 1238 1237 1238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1231 1238 1231 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 1272 1276 1272 1276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 1310 1314 1310 1314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 1340 1344 1340 1344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 1371 1375 1371 1375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 1432 1433 1432 1433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1438 1439 1438 1439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1424 1439 1424 1439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, <italic>B</italic> and <italic>C</italic></xref>
###xml 1549 1553 1549 1553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 1940 1941 1940 1941 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1934 1941 1934 1941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>D</italic></xref>
Evidence for a Second Dimerization Domain in PKD2-We initially generated three naturally occurring PKD2 mutants, one with a single missense change in the third transmembrane domain (D511V) and two others lacking the C-terminal homodimerization domain, L703X and R742X (Fig. 1). The D511V mutation has previously been shown to completely abolish PC2 channel activity whereas L703X and R742X have altered channel properties in some expression systems (12, 25). Relevant to the present study, D511V has been demonstrated to function as a dominant negative interfering allele in mIMCD3 (9) and LLC-PK1 cells (26). As previously shown for endogenous PC2 (10), full-length PKD2 could be detected mainly as monomers under normal reducing conditions on SDS-PAGE but as oligomers under non-reducing conditions (Fig. 2A). Apart from prominent dimers, several other high molecular weight bands were detected under non-reducing conditions. These could represent homophilic binding between PC2 subunits or heterophilic interactions with other proteins. PKD2-D511V, showed a similar pattern of oligomerization under these conditions (data not shown). Unexpectedly we found that PKD2-L703X, could still form dimers under non-reducing conditions (Fig. 2A). Similar results were found for PKD2-R742X (not shown). As predicted, PKD2-D511V bound to wild-type PKD2, but unexpectedly, so did PKD2-R742X in co-immunoprecipitation (co-IP) assays (Fig. 2, B and C). To exclude the effect of the epitope tags in the interaction, we repeated these experiments with different PKD2 full-length (Myc-tagged) and mutant (C-terminal HA-tagged) constructs and obtained similar results (data not shown). We therefore hypothesized that a proximal interacting domain could lie upstream of the previously described distal C-terminal domain, possibly in the N terminus. Indeed, the isolated PC2 N-terminal domain (NT2-(1-223)) could interact with itself in HEK293 cells (Fig. 2D).
###end p 23
###begin p 24
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 1.</label>
###xml 9 108 9 108 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Schematic diagram of epitope-tagged PKD2 constructs used in the study with their predicted domains.</bold>
###xml 130 134 130 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 9 302 9 302 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="25"><bold>Schematic diagram of epitope-tagged PKD2 constructs used in the study with their predicted domains.</bold> Apart from wild-type <italic>PKD2</italic>, a site-specific mutant (D511V), two mutants with truncations of the C terminus (R742X and L703X), and the isolated N-terminal domain (L224X) were generated for study.</p>
###xml 9 302 9 302 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="25"><bold>Schematic diagram of epitope-tagged PKD2 constructs used in the study with their predicted domains.</bold> Apart from wild-type <italic>PKD2</italic>, a site-specific mutant (D511V), two mutants with truncations of the C terminus (R742X and L703X), and the isolated N-terminal domain (L224X) were generated for study.</p></caption>
###xml 302 302 302 302 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0440853210001"/>
###xml 0 302 0 302 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig1"><label>FIGURE 1.</label><caption><p textid="25"><bold>Schematic diagram of epitope-tagged PKD2 constructs used in the study with their predicted domains.</bold> Apart from wild-type <italic>PKD2</italic>, a site-specific mutant (D511V), two mutants with truncations of the C terminus (R742X and L703X), and the isolated N-terminal domain (L224X) were generated for study.</p></caption><graphic xlink:href="zbc0440853210001"/></fig>
FIGURE 1.Schematic diagram of epitope-tagged PKD2 constructs used in the study with their predicted domains. Apart from wild-type PKD2, a site-specific mutant (D511V), two mutants with truncations of the C terminus (R742X and L703X), and the isolated N-terminal domain (L224X) were generated for study.
###end p 24
###begin p 25
###xml 0 99 0 99 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Schematic diagram of epitope-tagged PKD2 constructs used in the study with their predicted domains.</bold>
###xml 121 125 121 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
Schematic diagram of epitope-tagged PKD2 constructs used in the study with their predicted domains. Apart from wild-type PKD2, a site-specific mutant (D511V), two mutants with truncations of the C terminus (R742X and L703X), and the isolated N-terminal domain (L224X) were generated for study.
###end p 25
###begin p 26
###xml 0 62 0 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Defining the Dimerization Domain using Yeast Two-hybrid Assays</italic>
###xml 163 169 163 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 340 344 340 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e.</italic>
###xml 545 551 545 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 1151 1152 1151 1152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1145 1152 1145 1152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>C</italic></xref>
###xml 39 44 <span type="species:ncbi:4932">Yeast</span>
###xml 111 116 <span type="species:ncbi:4932">yeast</span>
###xml 171 176 <span type="species:ncbi:4932">yeast</span>
###xml 1213 1218 <span type="species:ncbi:9606">human</span>
###xml 1220 1225 <span type="species:ncbi:10090">mouse</span>
###xml 1231 1240 <span type="species:ncbi:7955">zebrafish</span>
###xml 1342 1347 <span type="species:ncbi:9606">human</span>
###xml 1348 1353 <span type="species:ncbi:10090">mouse</span>
###xml 1421 1426 <span type="species:ncbi:9606">human</span>
###xml 1431 1440 <span type="species:ncbi:7955">zebrafish</span>
Defining the Dimerization Domain using Yeast Two-hybrid Assays-To characterize and refine this domain further, yeast two-hybrid assays were performed. As shown in Fig. 3, yeast co-transformants containing NT2-(1-223)-pGBKT7 (bait) and NT2-(1-223)-pGADT7 (prey) were able to grow on selective media requiring the activation of two reporters i.e. HIS3 and ADE2. NT2 did not interact with the C terminus of PC2 (CT2, data not shown). Further studies were carried out to refine the minimal interacting region using deletion constructs. As showed in Fig. 3, the truncation NT2-(1-207) could still interact with NT2-(1-223), while truncations NT2-(1-177) and NT2-(1-198) lost the ability to interact with NT2-(1-223). Shorter sequences of NT2 such as NT2-(1-61) and NT2-(1-117) were unable to interact with full-length NT2-(1-223) (not shown). These results indicate that the region from codons 199-207 is an essential part of the N-terminal interacting domain. The sequence NT2-(178-223) showed a weaker interaction than NT2-(1-223) in our assay (data not shown) suggesting that flanking sequences might be important in determining binding affinity. Fig. 3C shows the high sequence conservation of this region between human, mouse, and zebrafish PC2. Between codons 190 and 207, 12 of 17 amino acids (70.6%) are identical or similar compared with human/mouse PC2. This contrasts with the minimal sequence conservation between human and zebrafish PC2 in the preceding sequence of NT2 (codons 119-189).
###end p 26
###begin p 27
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 2.</label>
###xml 9 92 9 92 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Biochemical evidence for a proximal dimerization sequence in the N terminus of PC2.</bold>
###xml 92 93 92 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 208 209 208 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 229 231 229 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NR</italic>
###xml 613 617 601 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g.</italic>
###xml 847 848 823 824 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 913 914 889 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1092 1093 1068 1069 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1712 1713 1687 1688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 9 1934 9 1909 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="28"><bold>Biochemical evidence for a proximal dimerization sequence in the N terminus of PC2.</bold><italic>A</italic>, detection of epitope-tagged wild-type and mutant PC2 expressed in HEK293 cells by immunoblotting under reducing (<italic>R</italic>) and non-reducing (<italic>NR</italic>) conditions in three individual samples. Note that both forms of PC2 are detected predominantly as monomers under reducing SDS-PAGE but that there are prominent slower migrating species visible under non-reducing states. For full-length PC2, apart from prominent dimeric species (&#8764;220 kDa), there are also higher bands suggestive of more complex oligomeric structures (<italic>e.g.</italic> tetramers). For L703X, the monomeric species are more notable than for wild-type PC2 under NR conditions but there is also detectable dimer formation (&#8764;150kDa). Calnexin was used as an endogenous control for loading. <sup>*</sup> indicates a minor nonspecific band detected by the HA antibody. <italic>B</italic>, coimmunoprecipitation of epitope-tagged PC2-D511V (D511VPk) and wild-type PC2 (HA-PKD2). PC2-D511V is predicted to retain both hetero- and homodimerization C-terminal domains. <italic>C</italic>, PC2 mutant lacking both C-terminal dimerization domains (HA PKD2 R742X) associates with wild-type PC2 (PKD2Pk). The p30 and pK antibodies only recognize C-terminal epitope in full-length PC2. However, the HA antibody, which only recognizes the mutant R742X was able to co-IP wild-type PC2 (PKD2Pk) suggesting an interacting sequence proximal to the truncation. 1 mg of total cell lysate was used for IP with HA or NIS (non-immune serum) and 0.1 mg (1/10) for IP with p30 as indicated. 30 &#956;g of lysate were loaded as a positive control. The converse experiment showed that p30 or pK antibodies could pull-down R742X. <italic>D</italic>, co-immunoprecipitation of HA-tagged N-terminal PC2 protein (NT2) containing the first 223 amino acids (L224X) with co-expressed Myc-tagged L224X. These results implied the existence of an N-terminal dimerization domain.</p>
###xml 9 1934 9 1909 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="28"><bold>Biochemical evidence for a proximal dimerization sequence in the N terminus of PC2.</bold><italic>A</italic>, detection of epitope-tagged wild-type and mutant PC2 expressed in HEK293 cells by immunoblotting under reducing (<italic>R</italic>) and non-reducing (<italic>NR</italic>) conditions in three individual samples. Note that both forms of PC2 are detected predominantly as monomers under reducing SDS-PAGE but that there are prominent slower migrating species visible under non-reducing states. For full-length PC2, apart from prominent dimeric species (&#8764;220 kDa), there are also higher bands suggestive of more complex oligomeric structures (<italic>e.g.</italic> tetramers). For L703X, the monomeric species are more notable than for wild-type PC2 under NR conditions but there is also detectable dimer formation (&#8764;150kDa). Calnexin was used as an endogenous control for loading. <sup>*</sup> indicates a minor nonspecific band detected by the HA antibody. <italic>B</italic>, coimmunoprecipitation of epitope-tagged PC2-D511V (D511VPk) and wild-type PC2 (HA-PKD2). PC2-D511V is predicted to retain both hetero- and homodimerization C-terminal domains. <italic>C</italic>, PC2 mutant lacking both C-terminal dimerization domains (HA PKD2 R742X) associates with wild-type PC2 (PKD2Pk). The p30 and pK antibodies only recognize C-terminal epitope in full-length PC2. However, the HA antibody, which only recognizes the mutant R742X was able to co-IP wild-type PC2 (PKD2Pk) suggesting an interacting sequence proximal to the truncation. 1 mg of total cell lysate was used for IP with HA or NIS (non-immune serum) and 0.1 mg (1/10) for IP with p30 as indicated. 30 &#956;g of lysate were loaded as a positive control. The converse experiment showed that p30 or pK antibodies could pull-down R742X. <italic>D</italic>, co-immunoprecipitation of HA-tagged N-terminal PC2 protein (NT2) containing the first 223 amino acids (L224X) with co-expressed Myc-tagged L224X. These results implied the existence of an N-terminal dimerization domain.</p></caption>
###xml 1934 1934 1909 1909 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0440853210002"/>
###xml 0 1934 0 1909 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig2"><label>FIGURE 2.</label><caption><p textid="28"><bold>Biochemical evidence for a proximal dimerization sequence in the N terminus of PC2.</bold><italic>A</italic>, detection of epitope-tagged wild-type and mutant PC2 expressed in HEK293 cells by immunoblotting under reducing (<italic>R</italic>) and non-reducing (<italic>NR</italic>) conditions in three individual samples. Note that both forms of PC2 are detected predominantly as monomers under reducing SDS-PAGE but that there are prominent slower migrating species visible under non-reducing states. For full-length PC2, apart from prominent dimeric species (&#8764;220 kDa), there are also higher bands suggestive of more complex oligomeric structures (<italic>e.g.</italic> tetramers). For L703X, the monomeric species are more notable than for wild-type PC2 under NR conditions but there is also detectable dimer formation (&#8764;150kDa). Calnexin was used as an endogenous control for loading. <sup>*</sup> indicates a minor nonspecific band detected by the HA antibody. <italic>B</italic>, coimmunoprecipitation of epitope-tagged PC2-D511V (D511VPk) and wild-type PC2 (HA-PKD2). PC2-D511V is predicted to retain both hetero- and homodimerization C-terminal domains. <italic>C</italic>, PC2 mutant lacking both C-terminal dimerization domains (HA PKD2 R742X) associates with wild-type PC2 (PKD2Pk). The p30 and pK antibodies only recognize C-terminal epitope in full-length PC2. However, the HA antibody, which only recognizes the mutant R742X was able to co-IP wild-type PC2 (PKD2Pk) suggesting an interacting sequence proximal to the truncation. 1 mg of total cell lysate was used for IP with HA or NIS (non-immune serum) and 0.1 mg (1/10) for IP with p30 as indicated. 30 &#956;g of lysate were loaded as a positive control. The converse experiment showed that p30 or pK antibodies could pull-down R742X. <italic>D</italic>, co-immunoprecipitation of HA-tagged N-terminal PC2 protein (NT2) containing the first 223 amino acids (L224X) with co-expressed Myc-tagged L224X. These results implied the existence of an N-terminal dimerization domain.</p></caption><graphic xlink:href="zbc0440853210002"/></fig>
FIGURE 2.Biochemical evidence for a proximal dimerization sequence in the N terminus of PC2.A, detection of epitope-tagged wild-type and mutant PC2 expressed in HEK293 cells by immunoblotting under reducing (R) and non-reducing (NR) conditions in three individual samples. Note that both forms of PC2 are detected predominantly as monomers under reducing SDS-PAGE but that there are prominent slower migrating species visible under non-reducing states. For full-length PC2, apart from prominent dimeric species (approximately220 kDa), there are also higher bands suggestive of more complex oligomeric structures (e.g. tetramers). For L703X, the monomeric species are more notable than for wild-type PC2 under NR conditions but there is also detectable dimer formation (approximately150kDa). Calnexin was used as an endogenous control for loading. * indicates a minor nonspecific band detected by the HA antibody. B, coimmunoprecipitation of epitope-tagged PC2-D511V (D511VPk) and wild-type PC2 (HA-PKD2). PC2-D511V is predicted to retain both hetero- and homodimerization C-terminal domains. C, PC2 mutant lacking both C-terminal dimerization domains (HA PKD2 R742X) associates with wild-type PC2 (PKD2Pk). The p30 and pK antibodies only recognize C-terminal epitope in full-length PC2. However, the HA antibody, which only recognizes the mutant R742X was able to co-IP wild-type PC2 (PKD2Pk) suggesting an interacting sequence proximal to the truncation. 1 mg of total cell lysate was used for IP with HA or NIS (non-immune serum) and 0.1 mg (1/10) for IP with p30 as indicated. 30 mug of lysate were loaded as a positive control. The converse experiment showed that p30 or pK antibodies could pull-down R742X. D, co-immunoprecipitation of HA-tagged N-terminal PC2 protein (NT2) containing the first 223 amino acids (L224X) with co-expressed Myc-tagged L224X. These results implied the existence of an N-terminal dimerization domain.
###end p 27
###begin p 28
###xml 0 83 0 83 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Biochemical evidence for a proximal dimerization sequence in the N terminus of PC2.</bold>
###xml 83 84 83 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 199 200 199 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 220 222 220 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NR</italic>
###xml 604 608 592 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g.</italic>
###xml 838 839 814 815 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 904 905 880 881 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1083 1084 1059 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1703 1704 1678 1679 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
Biochemical evidence for a proximal dimerization sequence in the N terminus of PC2.A, detection of epitope-tagged wild-type and mutant PC2 expressed in HEK293 cells by immunoblotting under reducing (R) and non-reducing (NR) conditions in three individual samples. Note that both forms of PC2 are detected predominantly as monomers under reducing SDS-PAGE but that there are prominent slower migrating species visible under non-reducing states. For full-length PC2, apart from prominent dimeric species (approximately220 kDa), there are also higher bands suggestive of more complex oligomeric structures (e.g. tetramers). For L703X, the monomeric species are more notable than for wild-type PC2 under NR conditions but there is also detectable dimer formation (approximately150kDa). Calnexin was used as an endogenous control for loading. * indicates a minor nonspecific band detected by the HA antibody. B, coimmunoprecipitation of epitope-tagged PC2-D511V (D511VPk) and wild-type PC2 (HA-PKD2). PC2-D511V is predicted to retain both hetero- and homodimerization C-terminal domains. C, PC2 mutant lacking both C-terminal dimerization domains (HA PKD2 R742X) associates with wild-type PC2 (PKD2Pk). The p30 and pK antibodies only recognize C-terminal epitope in full-length PC2. However, the HA antibody, which only recognizes the mutant R742X was able to co-IP wild-type PC2 (PKD2Pk) suggesting an interacting sequence proximal to the truncation. 1 mg of total cell lysate was used for IP with HA or NIS (non-immune serum) and 0.1 mg (1/10) for IP with p30 as indicated. 30 mug of lysate were loaded as a positive control. The converse experiment showed that p30 or pK antibodies could pull-down R742X. D, co-immunoprecipitation of HA-tagged N-terminal PC2 protein (NT2) containing the first 223 amino acids (L224X) with co-expressed Myc-tagged L224X. These results implied the existence of an N-terminal dimerization domain.
###end p 28
###begin p 29
###xml 0 82 0 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Induction of Zebrafish Pronephric Cyst Formation by Co-injection of PKD2-L223 mRNA</italic>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref24">24</xref>
###xml 210 214 210 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pkd2</italic>
###xml 445 449 445 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 456 458 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref24">24</xref>
###xml 703 710 703 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl1">Table 1</xref>
###xml 839 843 839 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 923 927 923 927 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 962 963 962 963 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 956 963 956 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>E</italic></xref>
###xml 1009 1013 1009 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pkd2</italic>
###xml 1043 1044 1043 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1037 1044 1037 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>D</italic></xref>
###xml 1069 1075 1069 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4</xref>
###xml 1093 1097 1093 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 1114 1118 1114 1118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pkd2</italic>
###xml 1145 1149 1145 1149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pkd2</italic>
###xml 1180 1181 1180 1181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1174 1181 1174 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>F</italic></xref>
###xml 1200 1204 1200 1204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 1284 1288 1284 1288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 1384 1385 1384 1385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 13 22 <span type="species:ncbi:7955">Zebrafish</span>
###xml 118 127 <span type="species:ncbi:7955">zebrafish</span>
###xml 164 169 <span type="species:ncbi:9606">human</span>
###xml 200 209 <span type="species:ncbi:7955">zebrafish</span>
###xml 439 444 <span type="species:ncbi:9606">human</span>
###xml 506 512 <span type="species:ncbi:9606">humans</span>
###xml 517 526 <span type="species:ncbi:7955">zebrafish</span>
###xml 549 558 <span type="species:ncbi:7955">zebrafish</span>
###xml 833 838 <span type="species:ncbi:9606">human</span>
###xml 885 894 <span type="species:ncbi:7955">zebrafish</span>
###xml 917 922 <span type="species:ncbi:9606">human</span>
###xml 1298 1307 <span type="species:ncbi:7955">zebrafish</span>
Induction of Zebrafish Pronephric Cyst Formation by Co-injection of PKD2-L223 mRNA-We have previously established the zebrafish as a relevant model system to study human ADPKD (19, 24). Disruption of zebrafish pkd2 expression with morpholinos (MO) results in cyst formation in the glomerulus and pronephric tubules in conjunction with changes in body axis curvature and hydrocephalus. All of these features were rescued by co-injection of human PKD2 mRNA (19, 24). Because of sequence conservation between humans and zebrafish, we reasoned that the zebrafish model could be used to test the functionality of the N-terminal domain of PC2 by a dominant negative mechanism. These results are summarized in Table 1. To establish if a dominant negative effect could be observed in this system, we initially tested the effect of injecting human PKD2-D511V synthetic mRNA into one-cell stage zebrafish embryos. Injection of human PKD2-D511V synthetic mRNA alone (Fig. 4E) induced the same phenotypic changes seen in pkd2ATGMO-injected embryos (Fig. 4D). Moreover, as shown in Fig. 4, co-injection of PKD2-D511V mRNA with pkd2ATGMO could not rescue the pkd2ATGMO induced phenotype (Fig. 4F) unlike wild-type PKD2 mRNA. Therefore, these results established a a dominant negative mechanism for PKD2-D511V in zebrafish and fully supported previous data using the same construct in mIMCD3 cells (9).
###end p 29
###begin p 30
###xml 0 7 0 7 <label xmlns:xlink="http://www.w3.org/1999/xlink">TABLE 1</label>
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 71 75 71 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pkd2</italic>
###xml 7 115 7 115 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Zebrafish phenotypes after injection of capped <italic>PKD2</italic> mRNA and/or <italic>pkd2</italic> morpholino at the one-cell embryo stage</bold>
###xml 7 115 7 115 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="31"><bold>Zebrafish phenotypes after injection of capped <italic>PKD2</italic> mRNA and/or <italic>pkd2</italic> morpholino at the one-cell embryo stage</bold></p>
###xml 7 115 7 115 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="31"><bold>Zebrafish phenotypes after injection of capped <italic>PKD2</italic> mRNA and/or <italic>pkd2</italic> morpholino at the one-cell embryo stage</bold></p></caption>
###xml 115 115 115 115 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"/>
###xml 115 137 115 137 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Total embryos injected</bold>
###xml 115 137 115 137 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>Total embryos injected</bold></th>
###xml 137 151 137 151 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Normal embryos</bold>
###xml 137 151 137 151 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>Normal embryos</bold></th>
###xml 151 180 151 180 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Cysts and body axis curvature</bold>
###xml 151 180 151 180 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>Cysts and body axis curvature</bold></th>
###xml 115 180 115 180 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th colspan="1" rowspan="1" align="center" valign="top"/><th colspan="1" rowspan="1" align="center" valign="top"><bold>Total embryos injected</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Normal embryos</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Cysts and body axis curvature</bold></th></tr>
###xml 115 180 115 180 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th colspan="1" rowspan="1" align="center" valign="top"/><th colspan="1" rowspan="1" align="center" valign="top"><bold>Total embryos injected</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Normal embryos</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Cysts and body axis curvature</bold></th></tr></thead>
###xml 180 195 180 195 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> A. Control MO </td>
###xml 195 200 195 200 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 303 </td>
###xml 200 212 200 212 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 303 (100%) </td>
###xml 212 220 212 220 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0 (0%) </td>
###xml 180 220 180 220 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> A. Control MO </td><td colspan="1" rowspan="1" align="center" valign="top"> 303 </td><td colspan="1" rowspan="1" align="center" valign="top"> 303 (100%) </td><td colspan="1" rowspan="1" align="center" valign="top"> 0 (0%) </td></tr>
###xml 230 239 230 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2-L177</italic>
###xml 220 239 220 239 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> B. Human <italic>PKD2-L177</italic></td>
###xml 239 244 239 244 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 254 </td>
###xml 244 255 244 255 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 250 (98%) </td>
###xml 255 263 255 263 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 4 (2%) </td>
###xml 220 263 220 263 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> B. Human <italic>PKD2-L177</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> 254 </td><td colspan="1" rowspan="1" align="center" valign="top"> 250 (98%) </td><td colspan="1" rowspan="1" align="center" valign="top"> 4 (2%) </td></tr>
###xml 273 282 273 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2-L223</italic>
###xml 263 282 263 282 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> C. Human <italic>PKD2-L223</italic></td>
###xml 282 287 282 287 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 252 </td>
###xml 287 296 287 296 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 20 (8%) </td>
###xml 296 307 296 307 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 232 (92%) </td>
###xml 263 307 263 307 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> C. Human <italic>PKD2-L223</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> 252 </td><td colspan="1" rowspan="1" align="center" valign="top"> 20 (8%) </td><td colspan="1" rowspan="1" align="center" valign="top"> 232 (92%) </td></tr>
###xml 311 320 311 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pkd2ATGMO</italic>
###xml 307 320 307 320 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> D. <italic>pkd2ATGMO</italic></td>
###xml 320 325 320 325 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 222 </td>
###xml 325 334 325 334 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 12 (5%) </td>
###xml 334 345 334 345 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 210 (95%) </td>
###xml 307 345 307 345 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> D. <italic>pkd2ATGMO</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> 222 </td><td colspan="1" rowspan="1" align="center" valign="top"> 12 (5%) </td><td colspan="1" rowspan="1" align="center" valign="top"> 210 (95%) </td></tr>
###xml 355 365 355 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2-D511V</italic>
###xml 345 365 345 365 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> E. Human <italic>PKD2-D511V</italic></td>
###xml 365 370 365 370 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 296 </td>
###xml 370 378 370 378 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 6 (5%) </td>
###xml 378 389 378 389 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 281 (95%) </td>
###xml 345 389 345 389 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> E. Human <italic>PKD2-D511V</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> 296 </td><td colspan="1" rowspan="1" align="center" valign="top"> 6 (5%) </td><td colspan="1" rowspan="1" align="center" valign="top"> 281 (95%) </td></tr>
###xml 393 402 393 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pkd2ATGMO</italic>
###xml 411 421 411 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2-D511V</italic>
###xml 389 421 389 421 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> F. <italic>pkd2ATGMO</italic> + human <italic>PKD2-D511V</italic></td>
###xml 421 426 421 426 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 103 </td>
###xml 426 434 426 434 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 2 (2%) </td>
###xml 434 445 434 445 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 101 (98%) </td>
###xml 389 445 389 445 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> F. <italic>pkd2ATGMO</italic> + human <italic>PKD2-D511V</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> 103 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2 (2%) </td><td colspan="1" rowspan="1" align="center" valign="top"> 101 (98%) </td></tr>
###xml 180 445 180 445 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="1" rowspan="1" align="left" valign="top"> A. Control MO </td><td colspan="1" rowspan="1" align="center" valign="top"> 303 </td><td colspan="1" rowspan="1" align="center" valign="top"> 303 (100%) </td><td colspan="1" rowspan="1" align="center" valign="top"> 0 (0%) </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> B. Human <italic>PKD2-L177</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> 254 </td><td colspan="1" rowspan="1" align="center" valign="top"> 250 (98%) </td><td colspan="1" rowspan="1" align="center" valign="top"> 4 (2%) </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> C. Human <italic>PKD2-L223</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> 252 </td><td colspan="1" rowspan="1" align="center" valign="top"> 20 (8%) </td><td colspan="1" rowspan="1" align="center" valign="top"> 232 (92%) </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> D. <italic>pkd2ATGMO</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> 222 </td><td colspan="1" rowspan="1" align="center" valign="top"> 12 (5%) </td><td colspan="1" rowspan="1" align="center" valign="top"> 210 (95%) </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> E. Human <italic>PKD2-D511V</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> 296 </td><td colspan="1" rowspan="1" align="center" valign="top"> 6 (5%) </td><td colspan="1" rowspan="1" align="center" valign="top"> 281 (95%) </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> F. <italic>pkd2ATGMO</italic> + human <italic>PKD2-D511V</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> 103 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2 (2%) </td><td colspan="1" rowspan="1" align="center" valign="top"> 101 (98%) </td></tr></tbody>
###xml 115 445 115 445 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1" align="center" valign="top"/><th colspan="1" rowspan="1" align="center" valign="top"><bold>Total embryos injected</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Normal embryos</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Cysts and body axis curvature</bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"> A. Control MO </td><td colspan="1" rowspan="1" align="center" valign="top"> 303 </td><td colspan="1" rowspan="1" align="center" valign="top"> 303 (100%) </td><td colspan="1" rowspan="1" align="center" valign="top"> 0 (0%) </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> B. Human <italic>PKD2-L177</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> 254 </td><td colspan="1" rowspan="1" align="center" valign="top"> 250 (98%) </td><td colspan="1" rowspan="1" align="center" valign="top"> 4 (2%) </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> C. Human <italic>PKD2-L223</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> 252 </td><td colspan="1" rowspan="1" align="center" valign="top"> 20 (8%) </td><td colspan="1" rowspan="1" align="center" valign="top"> 232 (92%) </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> D. <italic>pkd2ATGMO</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> 222 </td><td colspan="1" rowspan="1" align="center" valign="top"> 12 (5%) </td><td colspan="1" rowspan="1" align="center" valign="top"> 210 (95%) </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> E. Human <italic>PKD2-D511V</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> 296 </td><td colspan="1" rowspan="1" align="center" valign="top"> 6 (5%) </td><td colspan="1" rowspan="1" align="center" valign="top"> 281 (95%) </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> F. <italic>pkd2ATGMO</italic> + human <italic>PKD2-D511V</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> 103 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2 (2%) </td><td colspan="1" rowspan="1" align="center" valign="top"> 101 (98%) </td></tr></tbody></table>
###xml 0 445 0 445 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="tbl1"><label>TABLE 1</label><caption><p textid="31"><bold>Zebrafish phenotypes after injection of capped <italic>PKD2</italic> mRNA and/or <italic>pkd2</italic> morpholino at the one-cell embryo stage</bold></p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1" align="center" valign="top"/><th colspan="1" rowspan="1" align="center" valign="top"><bold>Total embryos injected</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Normal embryos</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Cysts and body axis curvature</bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"> A. Control MO </td><td colspan="1" rowspan="1" align="center" valign="top"> 303 </td><td colspan="1" rowspan="1" align="center" valign="top"> 303 (100%) </td><td colspan="1" rowspan="1" align="center" valign="top"> 0 (0%) </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> B. Human <italic>PKD2-L177</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> 254 </td><td colspan="1" rowspan="1" align="center" valign="top"> 250 (98%) </td><td colspan="1" rowspan="1" align="center" valign="top"> 4 (2%) </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> C. Human <italic>PKD2-L223</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> 252 </td><td colspan="1" rowspan="1" align="center" valign="top"> 20 (8%) </td><td colspan="1" rowspan="1" align="center" valign="top"> 232 (92%) </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> D. <italic>pkd2ATGMO</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> 222 </td><td colspan="1" rowspan="1" align="center" valign="top"> 12 (5%) </td><td colspan="1" rowspan="1" align="center" valign="top"> 210 (95%) </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> E. Human <italic>PKD2-D511V</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> 296 </td><td colspan="1" rowspan="1" align="center" valign="top"> 6 (5%) </td><td colspan="1" rowspan="1" align="center" valign="top"> 281 (95%) </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> F. <italic>pkd2ATGMO</italic> + human <italic>PKD2-D511V</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> 103 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2 (2%) </td><td colspan="1" rowspan="1" align="center" valign="top"> 101 (98%) </td></tr></tbody></table></table-wrap>
###xml 224 229 <span type="species:ncbi:9606">Human</span>
###xml 267 272 <span type="species:ncbi:9606">Human</span>
###xml 349 354 <span type="species:ncbi:9606">Human</span>
###xml 405 410 <span type="species:ncbi:9606">human</span>
TABLE 1Zebrafish phenotypes after injection of capped PKD2 mRNA and/or pkd2 morpholino at the one-cell embryo stageTotal embryos injectedNormal embryosCysts and body axis curvature A. Control MO  303  303 (100%)  0 (0%)  B. Human PKD2-L177 254  250 (98%)  4 (2%)  C. Human PKD2-L223 252  20 (8%)  232 (92%)  D. pkd2ATGMO 222  12 (5%)  210 (95%)  E. Human PKD2-D511V 296  6 (5%)  281 (95%)  F. pkd2ATGMO + human PKD2-D511V 103  2 (2%)  101 (98%)
###end p 30
###begin p 31
###xml 47 51 47 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 64 68 64 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pkd2</italic>
###xml 0 108 0 108 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Zebrafish phenotypes after injection of capped <italic>PKD2</italic> mRNA and/or <italic>pkd2</italic> morpholino at the one-cell embryo stage</bold>
###xml 0 9 <span type="species:ncbi:7955">Zebrafish</span>
Zebrafish phenotypes after injection of capped PKD2 mRNA and/or pkd2 morpholino at the one-cell embryo stage
###end p 31
###begin p 32
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 3.</label>
###xml 9 95 9 95 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Dimerization of the polycystin-2 N terminus (NT2) detected by yeast two-hybrid assays.</bold>
###xml 95 96 95 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 177 178 177 178 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 211 215 211 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HIS3</italic>
###xml 220 224 220 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADE2</italic>
###xml 542 543 542 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 713 724 713 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left column</italic>
###xml 738 740 738 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BD</italic>
###xml 781 793 781 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right column</italic>
###xml 807 809 807 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AD</italic>
###xml 842 853 842 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left column</italic>
###xml 931 932 931 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1151 1152 1151 1152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1360 1368 1360 1368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">asterisk</italic>
###xml 1370 1371 1370 1371 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 1380 1391 1380 1391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom line</italic>
###xml 1622 1627 1622 1627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Danio</italic>
###xml 1693 1705 1693 1705 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Homo sapiens</italic>
###xml 1716 1728 1716 1728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mus musculus</italic>
###xml 1739 1749 1739 1749 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bos taurus</italic>
###xml 1760 1773 1760 1773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gallus gallus</italic>
###xml 1788 1799 1788 1799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Danio rerio</italic>
###xml 9 1801 9 1801 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="33"><bold>Dimerization of the polycystin-2 N terminus (NT2) detected by yeast two-hybrid assays.</bold><italic>A</italic>, growth of yeast co-transformants cultured on selective media S.D./-LTH with 2 m<sc>m</sc> 3-AT and S.D./-LTAH to activate <italic>HIS3</italic> and <italic>ADE2</italic> selection markers, respectively. The pairs of NT2 sequences tested are numbered from 1&#8211;4 and their sequences indicated. Constructs pGBKT7&#8211;53 (p53) and pGBADT7-T (SV40-T antigen) were used as a pair of positive controls while pGBAD-B-CT1 (4107&#8211;4227) and pACT2-B-CT2 (680&#8211;742) were used as a pair of negative controls. <italic>B</italic>, truncations of the N terminus of polycystin-2 (NT2) marked by the number of starting and ending amino acid residue and their interaction with NT2. The fragments on the <italic>left column</italic> are in bait (<italic>BD</italic>) constructs, while the fragments in the <italic>right column</italic> are in prey (<italic>AD</italic>) constructs. The numbers in the <italic>left column</italic> indicate the pairs of NT2 constructs tested and correspond to those shown in <italic>A</italic>. Positive (interaction) and negative results are indicated by +++, ++, +, and - for the appearance of positive growth on selective medium within 24 h, 48 h, and 3&#8211;7 days or no positive growth in 2 weeks, respectively. <italic>C</italic>, multiple sequence alignment of PC2 orthologues from different species overlapping with the sequence of human NT2-(190&#8211;238). Amino acids which show perfect conservation down to zebrafish are indicated by an <italic>asterisk</italic> (<sup>*</sup>) in the <italic>bottom line</italic>. In the region between amino acids 190 and 223, 23 of 33 amino acids (70%) are identical or similar. This contrasts with the region between amino acids 119 and 189 where only 1 of 70 amino acids (1.4%) show identity from human to <italic>Danio</italic>. The accession numbers for each sequence are as follows: Q13563 (<italic>Homo sapiens</italic>), O35245 (<italic>Mus musculus</italic>), Q4GZT3 (<italic>Bos taurus</italic>), Q5ZM00 (<italic>Gallus gallus</italic>), and Q6IVV8 (<italic>Danio rerio</italic>).</p>
###xml 9 1801 9 1801 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="33"><bold>Dimerization of the polycystin-2 N terminus (NT2) detected by yeast two-hybrid assays.</bold><italic>A</italic>, growth of yeast co-transformants cultured on selective media S.D./-LTH with 2 m<sc>m</sc> 3-AT and S.D./-LTAH to activate <italic>HIS3</italic> and <italic>ADE2</italic> selection markers, respectively. The pairs of NT2 sequences tested are numbered from 1&#8211;4 and their sequences indicated. Constructs pGBKT7&#8211;53 (p53) and pGBADT7-T (SV40-T antigen) were used as a pair of positive controls while pGBAD-B-CT1 (4107&#8211;4227) and pACT2-B-CT2 (680&#8211;742) were used as a pair of negative controls. <italic>B</italic>, truncations of the N terminus of polycystin-2 (NT2) marked by the number of starting and ending amino acid residue and their interaction with NT2. The fragments on the <italic>left column</italic> are in bait (<italic>BD</italic>) constructs, while the fragments in the <italic>right column</italic> are in prey (<italic>AD</italic>) constructs. The numbers in the <italic>left column</italic> indicate the pairs of NT2 constructs tested and correspond to those shown in <italic>A</italic>. Positive (interaction) and negative results are indicated by +++, ++, +, and - for the appearance of positive growth on selective medium within 24 h, 48 h, and 3&#8211;7 days or no positive growth in 2 weeks, respectively. <italic>C</italic>, multiple sequence alignment of PC2 orthologues from different species overlapping with the sequence of human NT2-(190&#8211;238). Amino acids which show perfect conservation down to zebrafish are indicated by an <italic>asterisk</italic> (<sup>*</sup>) in the <italic>bottom line</italic>. In the region between amino acids 190 and 223, 23 of 33 amino acids (70%) are identical or similar. This contrasts with the region between amino acids 119 and 189 where only 1 of 70 amino acids (1.4%) show identity from human to <italic>Danio</italic>. The accession numbers for each sequence are as follows: Q13563 (<italic>Homo sapiens</italic>), O35245 (<italic>Mus musculus</italic>), Q4GZT3 (<italic>Bos taurus</italic>), Q5ZM00 (<italic>Gallus gallus</italic>), and Q6IVV8 (<italic>Danio rerio</italic>).</p></caption>
###xml 1801 1801 1801 1801 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0440853210003"/>
###xml 0 1801 0 1801 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig3"><label>FIGURE 3.</label><caption><p textid="33"><bold>Dimerization of the polycystin-2 N terminus (NT2) detected by yeast two-hybrid assays.</bold><italic>A</italic>, growth of yeast co-transformants cultured on selective media S.D./-LTH with 2 m<sc>m</sc> 3-AT and S.D./-LTAH to activate <italic>HIS3</italic> and <italic>ADE2</italic> selection markers, respectively. The pairs of NT2 sequences tested are numbered from 1&#8211;4 and their sequences indicated. Constructs pGBKT7&#8211;53 (p53) and pGBADT7-T (SV40-T antigen) were used as a pair of positive controls while pGBAD-B-CT1 (4107&#8211;4227) and pACT2-B-CT2 (680&#8211;742) were used as a pair of negative controls. <italic>B</italic>, truncations of the N terminus of polycystin-2 (NT2) marked by the number of starting and ending amino acid residue and their interaction with NT2. The fragments on the <italic>left column</italic> are in bait (<italic>BD</italic>) constructs, while the fragments in the <italic>right column</italic> are in prey (<italic>AD</italic>) constructs. The numbers in the <italic>left column</italic> indicate the pairs of NT2 constructs tested and correspond to those shown in <italic>A</italic>. Positive (interaction) and negative results are indicated by +++, ++, +, and - for the appearance of positive growth on selective medium within 24 h, 48 h, and 3&#8211;7 days or no positive growth in 2 weeks, respectively. <italic>C</italic>, multiple sequence alignment of PC2 orthologues from different species overlapping with the sequence of human NT2-(190&#8211;238). Amino acids which show perfect conservation down to zebrafish are indicated by an <italic>asterisk</italic> (<sup>*</sup>) in the <italic>bottom line</italic>. In the region between amino acids 190 and 223, 23 of 33 amino acids (70%) are identical or similar. This contrasts with the region between amino acids 119 and 189 where only 1 of 70 amino acids (1.4%) show identity from human to <italic>Danio</italic>. The accession numbers for each sequence are as follows: Q13563 (<italic>Homo sapiens</italic>), O35245 (<italic>Mus musculus</italic>), Q4GZT3 (<italic>Bos taurus</italic>), Q5ZM00 (<italic>Gallus gallus</italic>), and Q6IVV8 (<italic>Danio rerio</italic>).</p></caption><graphic xlink:href="zbc0440853210003"/></fig>
###xml 71 76 <span type="species:ncbi:4932">yeast</span>
###xml 108 113 <span type="species:ncbi:4932">yeast</span>
###xml 387 391 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 1257 1262 <span type="species:ncbi:9606">human</span>
###xml 1330 1339 <span type="species:ncbi:7955">zebrafish</span>
###xml 1613 1618 <span type="species:ncbi:9606">human</span>
###xml 1693 1705 <span type="species:ncbi:9606">Homo sapiens</span>
###xml 1716 1728 <span type="species:ncbi:10090">Mus musculus</span>
###xml 1739 1749 <span type="species:ncbi:9913">Bos taurus</span>
###xml 1760 1773 <span type="species:ncbi:9031">Gallus gallus</span>
###xml 1788 1799 <span type="species:ncbi:7955">Danio rerio</span>
FIGURE 3.Dimerization of the polycystin-2 N terminus (NT2) detected by yeast two-hybrid assays.A, growth of yeast co-transformants cultured on selective media S.D./-LTH with 2 mm 3-AT and S.D./-LTAH to activate HIS3 and ADE2 selection markers, respectively. The pairs of NT2 sequences tested are numbered from 1-4 and their sequences indicated. Constructs pGBKT7-53 (p53) and pGBADT7-T (SV40-T antigen) were used as a pair of positive controls while pGBAD-B-CT1 (4107-4227) and pACT2-B-CT2 (680-742) were used as a pair of negative controls. B, truncations of the N terminus of polycystin-2 (NT2) marked by the number of starting and ending amino acid residue and their interaction with NT2. The fragments on the left column are in bait (BD) constructs, while the fragments in the right column are in prey (AD) constructs. The numbers in the left column indicate the pairs of NT2 constructs tested and correspond to those shown in A. Positive (interaction) and negative results are indicated by +++, ++, +, and - for the appearance of positive growth on selective medium within 24 h, 48 h, and 3-7 days or no positive growth in 2 weeks, respectively. C, multiple sequence alignment of PC2 orthologues from different species overlapping with the sequence of human NT2-(190-238). Amino acids which show perfect conservation down to zebrafish are indicated by an asterisk (*) in the bottom line. In the region between amino acids 190 and 223, 23 of 33 amino acids (70%) are identical or similar. This contrasts with the region between amino acids 119 and 189 where only 1 of 70 amino acids (1.4%) show identity from human to Danio. The accession numbers for each sequence are as follows: Q13563 (Homo sapiens), O35245 (Mus musculus), Q4GZT3 (Bos taurus), Q5ZM00 (Gallus gallus), and Q6IVV8 (Danio rerio).
###end p 32
###begin p 33
###xml 0 86 0 86 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Dimerization of the polycystin-2 N terminus (NT2) detected by yeast two-hybrid assays.</bold>
###xml 86 87 86 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 168 169 168 169 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 202 206 202 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HIS3</italic>
###xml 211 215 211 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADE2</italic>
###xml 533 534 533 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 704 715 704 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left column</italic>
###xml 729 731 729 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BD</italic>
###xml 772 784 772 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right column</italic>
###xml 798 800 798 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AD</italic>
###xml 833 844 833 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left column</italic>
###xml 922 923 922 923 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1142 1143 1142 1143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1351 1359 1351 1359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">asterisk</italic>
###xml 1361 1362 1361 1362 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 1371 1382 1371 1382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom line</italic>
###xml 1613 1618 1613 1618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Danio</italic>
###xml 1684 1696 1684 1696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Homo sapiens</italic>
###xml 1707 1719 1707 1719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mus musculus</italic>
###xml 1730 1740 1730 1740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bos taurus</italic>
###xml 1751 1764 1751 1764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gallus gallus</italic>
###xml 1779 1790 1779 1790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Danio rerio</italic>
###xml 62 67 <span type="species:ncbi:4932">yeast</span>
###xml 99 104 <span type="species:ncbi:4932">yeast</span>
###xml 378 382 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 1248 1253 <span type="species:ncbi:9606">human</span>
###xml 1321 1330 <span type="species:ncbi:7955">zebrafish</span>
###xml 1604 1609 <span type="species:ncbi:9606">human</span>
###xml 1684 1696 <span type="species:ncbi:9606">Homo sapiens</span>
###xml 1707 1719 <span type="species:ncbi:10090">Mus musculus</span>
###xml 1730 1740 <span type="species:ncbi:9913">Bos taurus</span>
###xml 1751 1764 <span type="species:ncbi:9031">Gallus gallus</span>
###xml 1779 1790 <span type="species:ncbi:7955">Danio rerio</span>
Dimerization of the polycystin-2 N terminus (NT2) detected by yeast two-hybrid assays.A, growth of yeast co-transformants cultured on selective media S.D./-LTH with 2 mm 3-AT and S.D./-LTAH to activate HIS3 and ADE2 selection markers, respectively. The pairs of NT2 sequences tested are numbered from 1-4 and their sequences indicated. Constructs pGBKT7-53 (p53) and pGBADT7-T (SV40-T antigen) were used as a pair of positive controls while pGBAD-B-CT1 (4107-4227) and pACT2-B-CT2 (680-742) were used as a pair of negative controls. B, truncations of the N terminus of polycystin-2 (NT2) marked by the number of starting and ending amino acid residue and their interaction with NT2. The fragments on the left column are in bait (BD) constructs, while the fragments in the right column are in prey (AD) constructs. The numbers in the left column indicate the pairs of NT2 constructs tested and correspond to those shown in A. Positive (interaction) and negative results are indicated by +++, ++, +, and - for the appearance of positive growth on selective medium within 24 h, 48 h, and 3-7 days or no positive growth in 2 weeks, respectively. C, multiple sequence alignment of PC2 orthologues from different species overlapping with the sequence of human NT2-(190-238). Amino acids which show perfect conservation down to zebrafish are indicated by an asterisk (*) in the bottom line. In the region between amino acids 190 and 223, 23 of 33 amino acids (70%) are identical or similar. This contrasts with the region between amino acids 119 and 189 where only 1 of 70 amino acids (1.4%) show identity from human to Danio. The accession numbers for each sequence are as follows: Q13563 (Homo sapiens), O35245 (Mus musculus), Q4GZT3 (Bos taurus), Q5ZM00 (Gallus gallus), and Q6IVV8 (Danio rerio).
###end p 33
###begin p 34
###xml 18 22 18 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 149 153 149 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pkd2</italic>
###xml 162 166 162 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 180 181 180 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 174 181 174 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>C</italic></xref>
###xml 193 197 193 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 303 307 303 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 365 366 365 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 359 366 359 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 395 399 395 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 489 490 489 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 483 490 483 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 514 518 514 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 526 530 526 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 540 544 540 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 651 652 651 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 645 652 645 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>G</italic></xref>
###xml 691 695 691 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 938 942 938 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 31 40 <span type="species:ncbi:7955">zebrafish</span>
###xml 297 302 <span type="species:ncbi:9606">human</span>
###xml 621 626 <span type="species:ncbi:9606">human</span>
Next, we injected PKD2-L223 in zebrafish embryos and tested whether it could result in a phenotype similar to the phenotype obtained by injection of pkd2ATGMO or PKD2-D511V. Fig. 4C shows that PKD2-L223 induced body axis curvature, pronephric cyst formation and hydrocephalus whereas injection of human PKD2-L177 mRNA lacking the dimerization domain did not (Fig. 4B). All injected embryos with PKD2-L177 exhibited normal histology as compared with embryos injected with control MO (Fig. 4A). Expression levels of PKD2-D511V, PKD2-L223 and PKD2-L177 were shown to be equivalent in injected embryos by nested RT-PCR using human-specific primers (Fig. 4G). In summary, these data suggest that PKD2-L223 must have interfered with wild-type PC2 and/or its interacting partners. However, because the N-terminal domain of PC2 has been shown not to interact with known C-terminal binding partners such as PKD1 or TRPC1, it is highly likely that PKD2-L223 mediated its effect by direct binding to wild-type PKD2.
###end p 34
###begin p 35
###xml 29 33 29 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 47 48 47 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 41 48 41 48 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>E</italic></xref>
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 70 71 70 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 64 71 64 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>C</italic></xref>
###xml 166 170 166 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pkd2</italic>
###xml 183 184 183 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 177 184 177 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>D</italic></xref>
###xml 229 233 229 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 243 247 243 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 115 124 <span type="species:ncbi:7955">zebrafish</span>
Embryos injected with either PKD2-D511V (Fig. 4E) or PKD2-L223 (Fig. 4C) mRNA all showed a reduction of endogenous zebrafish PC2 expression similar to that seen with pkd2ATGMO (Fig. 4D). These results raised the possibility that PKD2-D511V or PKD2-L223 may have bound to wild-type PKD2 and/or marked it for degradation. An alternative possibility was that the acute binding of the mutant protein could have directly inhibited surface channel activity resulting in cysts with degradation occurring as a later event.
###end p 35
###begin p 36
###xml 0 118 0 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Inducible Translocation of PKD2-(223) to the Plasma Membrane Inhibits Endogenous and Transfected PKD2 Surface Currents</italic>
###xml 138 142 138 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 291 292 291 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 285 292 285 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>F</italic></xref>
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 575 579 575 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 641 645 641 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 966 972 966 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5</xref>
###xml 1141 1142 1137 1138 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 1268 1269 1264 1265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1282 1283 1278 1279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1276 1283 1272 1279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>E</italic></xref>
###xml 1503 1505 1499 1501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
Inducible Translocation of PKD2-(223) to the Plasma Membrane Inhibits Endogenous and Transfected PKD2 Surface Currents-To address whether PKD2-1-223 could acutely inhibit surface PC2 channels, we exploited a novel ligand-induced (rapamycin) chemical dimerization system (summarized in Fig. 5F) based on the rapamycin-induced dimerization between FKBP and FRB (17). The FRB (FKBP-rapamycin binding) domain was fused to a plasma membrane targeting sequence of the Rho GTPase Lyn (LDR) while CFP-tagged FKBP (FK506- and rapamycin-binding protein) was fused to the N terminus of PKD2-(1-223) to generate CF-PKD2-(223). As a control, we utilized PKD2-(1-177) to generate CF-PKD2-(177). In the absence of rapamycin, both CF-PKD2 fusions are primarily expressed in the cytoplasm. On addition of rapamycin in the presence of the FRB domain (LDR plasmid), there was a rapid translocation of both fusion proteins to the plasma membrane in HEK293 (not shown) and mIMCD3 cells (Fig. 5) as shown by the loss of cytoplasmic CFP fluorescence in individual cells over time. Moreover, the decrease in fluorescent intensity (DeltaF) over baseline intensity (F0) triggered by rapamycin was significantly altered for cytosolic CFP compared with the nuclear signal in the presence of LDR (n = 6) (Fig. 5E). The translocated CFP signal clearly overlapped with the YFP signal of a co-expressed surface-localized protein, YFP-C1 (PKC). The original CF (CFP-FKBP-Inp54p) construct served as a positive control (data not shown) (21).
###end p 36
###begin p 37
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 4.</label>
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 9 127 9 127 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Human <italic>PKD2</italic>-L223 and D511V induce pronephric cysts in the zebrafish and downregulate zebrafish polycystin-2 expression.</bold>
###xml 127 128 127 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 252 255 252 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">glm</italic>
###xml 542 543 542 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 546 547 546 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 562 566 562 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 672 673 672 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 681 685 681 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 798 799 798 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 801 805 801 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pkd2</italic>
###xml 894 898 894 898 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pkd2</italic>
###xml 933 937 933 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pkd2</italic>
###xml 992 993 992 993 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1001 1005 1001 1005 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 1095 1096 1095 1096 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1129 1133 1129 1133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 1165 1169 1165 1169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pkd2</italic>
###xml 1260 1264 1260 1264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pkd2</italic>
###xml 1277 1278 1277 1278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1306 1310 1306 1310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 1312 1323 1312 1323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">upper panel</italic>
###xml 1341 1352 1338 1349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lower panel</italic>
###xml 1452 1456 1449 1453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 1463 1464 1460 1461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1470 1474 1467 1471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 1482 1483 1479 1480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1512 1516 1509 1513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pkd2</italic>
###xml 1523 1524 1520 1521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 9 1526 9 1523 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="38"><bold>Human <italic>PKD2</italic>-L223 and D511V induce pronephric cysts in the zebrafish and downregulate zebrafish polycystin-2 expression.</bold><italic>A</italic>, 48 hpf zebrafish injected with a control MO have a normal body; histology section of 48 hpf embryos showing a glomerulus (<italic>glm</italic>) in the midline and pronephric tubules connected to bilateral pronephric ducts. Endogenous zebrafish PC2, detected with a specific antibody that does not cross-react with human PC2, is distributed in the basolateral membranes and apical cilia in the anterior pronephric ducts (see also <italic>H</italic>). <italic>B</italic>, 48-hpf human <italic>PKD2</italic>-L177 mRNA-injected embryos show normal whole mount histology cross-section and zebrafish PC2 expression. <italic>C</italic>, human <italic>PKD2</italic>-L223 mRNA-injected embryos showing pronephric cysts, body axis curvature, and reduced zebrafish PC2 expression. <italic>D</italic>, <italic>pkd2</italic>ATGMO-injected embryos showing pronephric cysts, body axis curvature, and hydrocephalus. <italic>pkd2</italic>ATGMO blocked endogenous zebrafish <italic>pkd2</italic> translation leading to a reduction in PC2 expression. <italic>E</italic>, human <italic>PKD2</italic>-D511V mRNA-injected embryos also developed body axis curvature, cyst, and hydrocephalus. <italic>F</italic>, co-injection of 50 pg of human <italic>PKD2</italic>-D511V was unable to rescue the <italic>pkd2</italic>ATGMO phenotype and induced more severe body axis curvature, cysts, and hydrocephalus than <italic>pkd2</italic>ATGMO alone. <italic>G</italic>, RT-PCR analysis for human <italic>PKD2</italic> (<italic>upper panel</italic>) and &#946;-actin (<italic>lower panel</italic>) mRNA expression. Endogenous zebrafish PC2 expression is clearly down-regulated by co-injection of <italic>PKD2</italic>-L223 (<italic>C</italic>) and <italic>PKD2</italic>-D511V (<italic>E</italic>) mRNA to a similar level as <italic>pkd2</italic>ATGMO (<italic>D</italic>).</p>
###xml 9 1526 9 1523 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="38"><bold>Human <italic>PKD2</italic>-L223 and D511V induce pronephric cysts in the zebrafish and downregulate zebrafish polycystin-2 expression.</bold><italic>A</italic>, 48 hpf zebrafish injected with a control MO have a normal body; histology section of 48 hpf embryos showing a glomerulus (<italic>glm</italic>) in the midline and pronephric tubules connected to bilateral pronephric ducts. Endogenous zebrafish PC2, detected with a specific antibody that does not cross-react with human PC2, is distributed in the basolateral membranes and apical cilia in the anterior pronephric ducts (see also <italic>H</italic>). <italic>B</italic>, 48-hpf human <italic>PKD2</italic>-L177 mRNA-injected embryos show normal whole mount histology cross-section and zebrafish PC2 expression. <italic>C</italic>, human <italic>PKD2</italic>-L223 mRNA-injected embryos showing pronephric cysts, body axis curvature, and reduced zebrafish PC2 expression. <italic>D</italic>, <italic>pkd2</italic>ATGMO-injected embryos showing pronephric cysts, body axis curvature, and hydrocephalus. <italic>pkd2</italic>ATGMO blocked endogenous zebrafish <italic>pkd2</italic> translation leading to a reduction in PC2 expression. <italic>E</italic>, human <italic>PKD2</italic>-D511V mRNA-injected embryos also developed body axis curvature, cyst, and hydrocephalus. <italic>F</italic>, co-injection of 50 pg of human <italic>PKD2</italic>-D511V was unable to rescue the <italic>pkd2</italic>ATGMO phenotype and induced more severe body axis curvature, cysts, and hydrocephalus than <italic>pkd2</italic>ATGMO alone. <italic>G</italic>, RT-PCR analysis for human <italic>PKD2</italic> (<italic>upper panel</italic>) and &#946;-actin (<italic>lower panel</italic>) mRNA expression. Endogenous zebrafish PC2 expression is clearly down-regulated by co-injection of <italic>PKD2</italic>-L223 (<italic>C</italic>) and <italic>PKD2</italic>-D511V (<italic>E</italic>) mRNA to a similar level as <italic>pkd2</italic>ATGMO (<italic>D</italic>).</p></caption>
###xml 1526 1526 1523 1523 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0440853210004"/>
###xml 0 1526 0 1523 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig4"><label>FIGURE 4.</label><caption><p textid="38"><bold>Human <italic>PKD2</italic>-L223 and D511V induce pronephric cysts in the zebrafish and downregulate zebrafish polycystin-2 expression.</bold><italic>A</italic>, 48 hpf zebrafish injected with a control MO have a normal body; histology section of 48 hpf embryos showing a glomerulus (<italic>glm</italic>) in the midline and pronephric tubules connected to bilateral pronephric ducts. Endogenous zebrafish PC2, detected with a specific antibody that does not cross-react with human PC2, is distributed in the basolateral membranes and apical cilia in the anterior pronephric ducts (see also <italic>H</italic>). <italic>B</italic>, 48-hpf human <italic>PKD2</italic>-L177 mRNA-injected embryos show normal whole mount histology cross-section and zebrafish PC2 expression. <italic>C</italic>, human <italic>PKD2</italic>-L223 mRNA-injected embryos showing pronephric cysts, body axis curvature, and reduced zebrafish PC2 expression. <italic>D</italic>, <italic>pkd2</italic>ATGMO-injected embryos showing pronephric cysts, body axis curvature, and hydrocephalus. <italic>pkd2</italic>ATGMO blocked endogenous zebrafish <italic>pkd2</italic> translation leading to a reduction in PC2 expression. <italic>E</italic>, human <italic>PKD2</italic>-D511V mRNA-injected embryos also developed body axis curvature, cyst, and hydrocephalus. <italic>F</italic>, co-injection of 50 pg of human <italic>PKD2</italic>-D511V was unable to rescue the <italic>pkd2</italic>ATGMO phenotype and induced more severe body axis curvature, cysts, and hydrocephalus than <italic>pkd2</italic>ATGMO alone. <italic>G</italic>, RT-PCR analysis for human <italic>PKD2</italic> (<italic>upper panel</italic>) and &#946;-actin (<italic>lower panel</italic>) mRNA expression. Endogenous zebrafish PC2 expression is clearly down-regulated by co-injection of <italic>PKD2</italic>-L223 (<italic>C</italic>) and <italic>PKD2</italic>-D511V (<italic>E</italic>) mRNA to a similar level as <italic>pkd2</italic>ATGMO (<italic>D</italic>).</p></caption><graphic xlink:href="zbc0440853210004"/></fig>
###xml 9 14 <span type="species:ncbi:9606">Human</span>
###xml 66 75 <span type="species:ncbi:7955">zebrafish</span>
###xml 93 102 <span type="species:ncbi:7955">zebrafish</span>
###xml 137 146 <span type="species:ncbi:7955">zebrafish</span>
###xml 347 356 <span type="species:ncbi:7955">zebrafish</span>
###xml 427 432 <span type="species:ncbi:9606">human</span>
###xml 556 561 <span type="species:ncbi:9606">human</span>
###xml 646 655 <span type="species:ncbi:7955">zebrafish</span>
###xml 675 680 <span type="species:ncbi:9606">human</span>
###xml 772 781 <span type="species:ncbi:7955">zebrafish</span>
###xml 923 932 <span type="species:ncbi:7955">zebrafish</span>
###xml 995 1000 <span type="species:ncbi:9606">human</span>
###xml 1123 1128 <span type="species:ncbi:9606">human</span>
###xml 1300 1305 <span type="species:ncbi:9606">human</span>
###xml 1382 1391 <span type="species:ncbi:7955">zebrafish</span>
FIGURE 4.Human PKD2-L223 and D511V induce pronephric cysts in the zebrafish and downregulate zebrafish polycystin-2 expression.A, 48 hpf zebrafish injected with a control MO have a normal body; histology section of 48 hpf embryos showing a glomerulus (glm) in the midline and pronephric tubules connected to bilateral pronephric ducts. Endogenous zebrafish PC2, detected with a specific antibody that does not cross-react with human PC2, is distributed in the basolateral membranes and apical cilia in the anterior pronephric ducts (see also H). B, 48-hpf human PKD2-L177 mRNA-injected embryos show normal whole mount histology cross-section and zebrafish PC2 expression. C, human PKD2-L223 mRNA-injected embryos showing pronephric cysts, body axis curvature, and reduced zebrafish PC2 expression. D, pkd2ATGMO-injected embryos showing pronephric cysts, body axis curvature, and hydrocephalus. pkd2ATGMO blocked endogenous zebrafish pkd2 translation leading to a reduction in PC2 expression. E, human PKD2-D511V mRNA-injected embryos also developed body axis curvature, cyst, and hydrocephalus. F, co-injection of 50 pg of human PKD2-D511V was unable to rescue the pkd2ATGMO phenotype and induced more severe body axis curvature, cysts, and hydrocephalus than pkd2ATGMO alone. G, RT-PCR analysis for human PKD2 (upper panel) and beta-actin (lower panel) mRNA expression. Endogenous zebrafish PC2 expression is clearly down-regulated by co-injection of PKD2-L223 (C) and PKD2-D511V (E) mRNA to a similar level as pkd2ATGMO (D).
###end p 37
###begin p 38
###xml 6 10 6 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 0 118 0 118 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Human <italic>PKD2</italic>-L223 and D511V induce pronephric cysts in the zebrafish and downregulate zebrafish polycystin-2 expression.</bold>
###xml 118 119 118 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 243 246 243 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">glm</italic>
###xml 533 534 533 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 537 538 537 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 553 557 553 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 663 664 663 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 672 676 672 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 789 790 789 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 792 796 792 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pkd2</italic>
###xml 885 889 885 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pkd2</italic>
###xml 924 928 924 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pkd2</italic>
###xml 983 984 983 984 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 992 996 992 996 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 1086 1087 1086 1087 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1120 1124 1120 1124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 1156 1160 1156 1160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pkd2</italic>
###xml 1251 1255 1251 1255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pkd2</italic>
###xml 1268 1269 1268 1269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1297 1301 1297 1301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 1303 1314 1303 1314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">upper panel</italic>
###xml 1332 1343 1329 1340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lower panel</italic>
###xml 1443 1447 1440 1444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 1454 1455 1451 1452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1461 1465 1458 1462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 1473 1474 1470 1471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1503 1507 1500 1504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pkd2</italic>
###xml 1514 1515 1511 1512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 57 66 <span type="species:ncbi:7955">zebrafish</span>
###xml 84 93 <span type="species:ncbi:7955">zebrafish</span>
###xml 128 137 <span type="species:ncbi:7955">zebrafish</span>
###xml 338 347 <span type="species:ncbi:7955">zebrafish</span>
###xml 418 423 <span type="species:ncbi:9606">human</span>
###xml 547 552 <span type="species:ncbi:9606">human</span>
###xml 637 646 <span type="species:ncbi:7955">zebrafish</span>
###xml 666 671 <span type="species:ncbi:9606">human</span>
###xml 763 772 <span type="species:ncbi:7955">zebrafish</span>
###xml 914 923 <span type="species:ncbi:7955">zebrafish</span>
###xml 986 991 <span type="species:ncbi:9606">human</span>
###xml 1114 1119 <span type="species:ncbi:9606">human</span>
###xml 1291 1296 <span type="species:ncbi:9606">human</span>
###xml 1373 1382 <span type="species:ncbi:7955">zebrafish</span>
Human PKD2-L223 and D511V induce pronephric cysts in the zebrafish and downregulate zebrafish polycystin-2 expression.A, 48 hpf zebrafish injected with a control MO have a normal body; histology section of 48 hpf embryos showing a glomerulus (glm) in the midline and pronephric tubules connected to bilateral pronephric ducts. Endogenous zebrafish PC2, detected with a specific antibody that does not cross-react with human PC2, is distributed in the basolateral membranes and apical cilia in the anterior pronephric ducts (see also H). B, 48-hpf human PKD2-L177 mRNA-injected embryos show normal whole mount histology cross-section and zebrafish PC2 expression. C, human PKD2-L223 mRNA-injected embryos showing pronephric cysts, body axis curvature, and reduced zebrafish PC2 expression. D, pkd2ATGMO-injected embryos showing pronephric cysts, body axis curvature, and hydrocephalus. pkd2ATGMO blocked endogenous zebrafish pkd2 translation leading to a reduction in PC2 expression. E, human PKD2-D511V mRNA-injected embryos also developed body axis curvature, cyst, and hydrocephalus. F, co-injection of 50 pg of human PKD2-D511V was unable to rescue the pkd2ATGMO phenotype and induced more severe body axis curvature, cysts, and hydrocephalus than pkd2ATGMO alone. G, RT-PCR analysis for human PKD2 (upper panel) and beta-actin (lower panel) mRNA expression. Endogenous zebrafish PC2 expression is clearly down-regulated by co-injection of PKD2-L223 (C) and PKD2-D511V (E) mRNA to a similar level as pkd2ATGMO (D).
###end p 38
###begin p 39
###xml 0 6 0 6 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6</xref>
###xml 242 243 238 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 248 249 244 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 234 249 230 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6, <italic>A</italic> and <italic>D</italic></xref>
###xml 323 324 319 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 317 324 313 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6<italic>D</italic></xref>
###xml 445 446 437 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 439 446 431 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6<italic>B</italic></xref>
###xml 555 556 543 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 549 556 537 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6<italic>C</italic></xref>
###xml 697 698 683 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 729 730 713 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 774 775 758 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 1242 1243 1214 1215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 1310 1311 1282 1283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 1313 1315 1285 1287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref15">15</xref>
Fig. 6 shows that addition of rapamycin induced a time-dependent reduction in whole cell current amplitude of mIMCD3 cells transiently transfected with LDR+CF-PKD2-(223) cells from -23.7 +/- 0.9 pA/pF to -14 +/- 0.6 pA/pF at -100 mV (Fig. 6, A and D). The reduction in current amplitude was significant up to -40 mV (Fig. 6D). Rapamycin did not have an effect in untransfected (from -23.6 +/- 1.2 pA/pF to -22.7 +/- 1.2 pA/pF at -100 mV) (Fig. 6B) or LDR+CF-PKD2 (177)-transfected cells (from -23.5 +/- 1.4 pA/pF to -22.3 +/- 1.4 pA/pF at -100 mV) (Fig. 6C). It should be noted that constitutive overexpression of PKD2-D511V in these cells suppressed whole cell currents from -24.3 +/- 3.4 pA/pF (n = 9) to -10.3 +/- 2.28 pA/pF (n = 7) under identical recording conditions (9) suggesting a similar mechanism of whole cell current density inhibition by PKD2-D511V or PKD2-L223. The small difference in whole cell current density (approximately4 pA/pF) between PKD2-D511V and PKD2-L223 may be explained by the higher affinity of PKD2-D511V than PKD2-L223 for binding to wild-type PKD2 or binding of PKD2-D511V to other interacting partners of PKD2 such as TRPC1, which was shown to be required for basal activity of native PKD2 in these cells (9). In contrast, PKD2-L223 should not associate with PKD1 or TRPC1 (5, 15) and therefore its effect on whole cell current density should be specific to wild-type PKD2, at least based on existing data.
###end p 39
###begin p 40
###xml 55 59 55 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 90 94 90 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 166 170 166 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 190 194 190 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 325 326 321 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 331 332 327 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 317 332 313 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6, <italic>B</italic> and <italic>F</italic></xref>
###xml 334 344 330 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black plot</italic>
###xml 420 421 416 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 632 633 624 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 626 633 618 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6<italic>H</italic></xref>
###xml 648 652 640 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 678 679 670 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 672 679 664 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6<italic>F</italic></xref>
###xml 684 688 676 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 788 789 780 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 782 789 774 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6<italic>G</italic></xref>
###xml 900 904 892 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
To further confirm the specificity of CF-PKD2-(223) on PKD2, we overexpressed full-length PKD2 and tested the effect of CF-PKD2-(177) or CF-PKD2-(223) on transfected PKD2. Overexpression of PKD2 resulted in an increase in overall whole cell current density from -23.6 +/- 1.2 pA/pF to -45.4 +/- 1.8 pA/pF at -100 mV (Fig. 6, B and F, black plot), consistent with the formation of active channels at the plasma membrane (9). Addition of rapamycin to the bath induced a time-dependent reduction in whole cell currents in PKD2-, LDR-, and CF-PKD2-(223)-cotransfected cells from -43.5 +/- 1 pA/pF to -21.8 +/- 1 pA/pF at -100 mV (Fig. 6H). However, in PKD2-transfected alone (Fig. 6F) or PKD2-, LDR-, and CF-PKD2-(177)-cotransfected cells, rapamycin did not affect whole cell currents (Fig. 6G). These data provide direct evidence for a dominant negative effect of CF-PKD2-(223) on native or transfected PKD2 surface channel activity. In this system, binding of PKD2-L223 resulted in acute inhibition of channel activity because the effect was observed almost immediately following induced translocation of PKD2-L223 to the plasma membrane.
###end p 40
###begin p 41
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 5.</label>
###xml 9 84 9 84 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Rapamycin-induced translocation of CFP-PKD2 fusions to the plasma membrane.</bold>
###xml 84 87 84 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#8211;D</italic>
###xml 236 252 236 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left hand panels</italic>
###xml 277 281 277 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">blue</italic>
###xml 288 301 288 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">middle panels</italic>
###xml 319 323 319 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">blue</italic>
###xml 369 372 369 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rap</italic>
###xml 379 380 378 379 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 404 416 403 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right panels</italic>
###xml 436 441 435 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 856 857 855 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 967 968 962 963 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 1073 1074 1068 1069 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1081 1082 1076 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1219 1221 1214 1216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PM</italic>
###xml 9 1702 9 1697 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="42"><bold>Rapamycin-induced translocation of CFP-PKD2 fusions to the plasma membrane.</bold><italic>A&#8211;D</italic>, CFP fluorescent images in live mIMCD3 cells co-transfected with the plasmids CF-PKD2-(177) or CF-PKD2-(223) in the presence or absence of LDR. The <italic>left hand panels</italic> represent baseline CFP (<italic>blue</italic>), the <italic>middle panels</italic> are CFP signals (<italic>blue</italic>) 5&#8211;45 s following the addition of rapamycin (<italic>Rap</italic>, 10 &#956;<sc>m</sc>) to the medium and the <italic>right panels</italic>, YFP fluorescence (<italic>green</italic>) of the fusion protein, YFP-C1-(PKC), which is constitutively localized at the plasma membrane. The translocation of both CFP-PKD2 fusion proteins induced by Rap in the presence of LDR can be seen graphically by the rapid reduction in the cytoplasmic CFP signal within the time frame shown (5&#8211;45 s). In contrast, nuclear expression of both fusion proteins is present at baseline but does not change following Rap. <italic>E</italic>, change in cytosolic CFP fluorescence intensity (&#916;F) expressed as a ratio of baseline CFP fluorescence (F<sub>0</sub>) was significantly altered compared with nuclear CFP fluorescence following Rap in the presence of LDR (<italic>n</italic> = 6). <italic>F</italic>, schematic diagram of the rapamycin-induced chemical dimerization strategy used to translocate CFP-PKD2 fusions to the plasma membrane (<italic>PM</italic>). The FRB (FKBP-rapamycin binding) domain was fused to a plasma membrane targeting sequence of the Rho GTPase Lyn (LDR), while CFP-tagged FKBP (FK506- and rapamycin-binding protein) was fused to the N terminus of PKD2 (1&#8211;177 or 1&#8211;223) to generate CF-PKD2-(177) and CF-PKD2-(223), respectively. Addition of Rap induces rapid heterodimerization between the PM-anchored FRB and FKBP fusion proteins, thus bringing the CF-PKD2 fusions into close proximity of PM-located PKD2 channels.</p>
###xml 9 1702 9 1697 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="42"><bold>Rapamycin-induced translocation of CFP-PKD2 fusions to the plasma membrane.</bold><italic>A&#8211;D</italic>, CFP fluorescent images in live mIMCD3 cells co-transfected with the plasmids CF-PKD2-(177) or CF-PKD2-(223) in the presence or absence of LDR. The <italic>left hand panels</italic> represent baseline CFP (<italic>blue</italic>), the <italic>middle panels</italic> are CFP signals (<italic>blue</italic>) 5&#8211;45 s following the addition of rapamycin (<italic>Rap</italic>, 10 &#956;<sc>m</sc>) to the medium and the <italic>right panels</italic>, YFP fluorescence (<italic>green</italic>) of the fusion protein, YFP-C1-(PKC), which is constitutively localized at the plasma membrane. The translocation of both CFP-PKD2 fusion proteins induced by Rap in the presence of LDR can be seen graphically by the rapid reduction in the cytoplasmic CFP signal within the time frame shown (5&#8211;45 s). In contrast, nuclear expression of both fusion proteins is present at baseline but does not change following Rap. <italic>E</italic>, change in cytosolic CFP fluorescence intensity (&#916;F) expressed as a ratio of baseline CFP fluorescence (F<sub>0</sub>) was significantly altered compared with nuclear CFP fluorescence following Rap in the presence of LDR (<italic>n</italic> = 6). <italic>F</italic>, schematic diagram of the rapamycin-induced chemical dimerization strategy used to translocate CFP-PKD2 fusions to the plasma membrane (<italic>PM</italic>). The FRB (FKBP-rapamycin binding) domain was fused to a plasma membrane targeting sequence of the Rho GTPase Lyn (LDR), while CFP-tagged FKBP (FK506- and rapamycin-binding protein) was fused to the N terminus of PKD2 (1&#8211;177 or 1&#8211;223) to generate CF-PKD2-(177) and CF-PKD2-(223), respectively. Addition of Rap induces rapid heterodimerization between the PM-anchored FRB and FKBP fusion proteins, thus bringing the CF-PKD2 fusions into close proximity of PM-located PKD2 channels.</p></caption>
###xml 1702 1702 1697 1697 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0440853210005"/>
###xml 0 1702 0 1697 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig5"><label>FIGURE 5.</label><caption><p textid="42"><bold>Rapamycin-induced translocation of CFP-PKD2 fusions to the plasma membrane.</bold><italic>A&#8211;D</italic>, CFP fluorescent images in live mIMCD3 cells co-transfected with the plasmids CF-PKD2-(177) or CF-PKD2-(223) in the presence or absence of LDR. The <italic>left hand panels</italic> represent baseline CFP (<italic>blue</italic>), the <italic>middle panels</italic> are CFP signals (<italic>blue</italic>) 5&#8211;45 s following the addition of rapamycin (<italic>Rap</italic>, 10 &#956;<sc>m</sc>) to the medium and the <italic>right panels</italic>, YFP fluorescence (<italic>green</italic>) of the fusion protein, YFP-C1-(PKC), which is constitutively localized at the plasma membrane. The translocation of both CFP-PKD2 fusion proteins induced by Rap in the presence of LDR can be seen graphically by the rapid reduction in the cytoplasmic CFP signal within the time frame shown (5&#8211;45 s). In contrast, nuclear expression of both fusion proteins is present at baseline but does not change following Rap. <italic>E</italic>, change in cytosolic CFP fluorescence intensity (&#916;F) expressed as a ratio of baseline CFP fluorescence (F<sub>0</sub>) was significantly altered compared with nuclear CFP fluorescence following Rap in the presence of LDR (<italic>n</italic> = 6). <italic>F</italic>, schematic diagram of the rapamycin-induced chemical dimerization strategy used to translocate CFP-PKD2 fusions to the plasma membrane (<italic>PM</italic>). The FRB (FKBP-rapamycin binding) domain was fused to a plasma membrane targeting sequence of the Rho GTPase Lyn (LDR), while CFP-tagged FKBP (FK506- and rapamycin-binding protein) was fused to the N terminus of PKD2 (1&#8211;177 or 1&#8211;223) to generate CF-PKD2-(177) and CF-PKD2-(223), respectively. Addition of Rap induces rapid heterodimerization between the PM-anchored FRB and FKBP fusion proteins, thus bringing the CF-PKD2 fusions into close proximity of PM-located PKD2 channels.</p></caption><graphic xlink:href="zbc0440853210005"/></fig>
FIGURE 5.Rapamycin-induced translocation of CFP-PKD2 fusions to the plasma membrane.A-D, CFP fluorescent images in live mIMCD3 cells co-transfected with the plasmids CF-PKD2-(177) or CF-PKD2-(223) in the presence or absence of LDR. The left hand panels represent baseline CFP (blue), the middle panels are CFP signals (blue) 5-45 s following the addition of rapamycin (Rap, 10 mum) to the medium and the right panels, YFP fluorescence (green) of the fusion protein, YFP-C1-(PKC), which is constitutively localized at the plasma membrane. The translocation of both CFP-PKD2 fusion proteins induced by Rap in the presence of LDR can be seen graphically by the rapid reduction in the cytoplasmic CFP signal within the time frame shown (5-45 s). In contrast, nuclear expression of both fusion proteins is present at baseline but does not change following Rap. E, change in cytosolic CFP fluorescence intensity (DeltaF) expressed as a ratio of baseline CFP fluorescence (F0) was significantly altered compared with nuclear CFP fluorescence following Rap in the presence of LDR (n = 6). F, schematic diagram of the rapamycin-induced chemical dimerization strategy used to translocate CFP-PKD2 fusions to the plasma membrane (PM). The FRB (FKBP-rapamycin binding) domain was fused to a plasma membrane targeting sequence of the Rho GTPase Lyn (LDR), while CFP-tagged FKBP (FK506- and rapamycin-binding protein) was fused to the N terminus of PKD2 (1-177 or 1-223) to generate CF-PKD2-(177) and CF-PKD2-(223), respectively. Addition of Rap induces rapid heterodimerization between the PM-anchored FRB and FKBP fusion proteins, thus bringing the CF-PKD2 fusions into close proximity of PM-located PKD2 channels.
###end p 41
###begin p 42
###xml 0 75 0 75 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Rapamycin-induced translocation of CFP-PKD2 fusions to the plasma membrane.</bold>
###xml 75 78 75 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#8211;D</italic>
###xml 227 243 227 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left hand panels</italic>
###xml 268 272 268 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">blue</italic>
###xml 279 292 279 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">middle panels</italic>
###xml 310 314 310 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">blue</italic>
###xml 360 363 360 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rap</italic>
###xml 370 371 369 370 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 395 407 394 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right panels</italic>
###xml 427 432 426 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 847 848 846 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 958 959 953 954 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 1064 1065 1059 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1072 1073 1067 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1210 1212 1205 1207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PM</italic>
Rapamycin-induced translocation of CFP-PKD2 fusions to the plasma membrane.A-D, CFP fluorescent images in live mIMCD3 cells co-transfected with the plasmids CF-PKD2-(177) or CF-PKD2-(223) in the presence or absence of LDR. The left hand panels represent baseline CFP (blue), the middle panels are CFP signals (blue) 5-45 s following the addition of rapamycin (Rap, 10 mum) to the medium and the right panels, YFP fluorescence (green) of the fusion protein, YFP-C1-(PKC), which is constitutively localized at the plasma membrane. The translocation of both CFP-PKD2 fusion proteins induced by Rap in the presence of LDR can be seen graphically by the rapid reduction in the cytoplasmic CFP signal within the time frame shown (5-45 s). In contrast, nuclear expression of both fusion proteins is present at baseline but does not change following Rap. E, change in cytosolic CFP fluorescence intensity (DeltaF) expressed as a ratio of baseline CFP fluorescence (F0) was significantly altered compared with nuclear CFP fluorescence following Rap in the presence of LDR (n = 6). F, schematic diagram of the rapamycin-induced chemical dimerization strategy used to translocate CFP-PKD2 fusions to the plasma membrane (PM). The FRB (FKBP-rapamycin binding) domain was fused to a plasma membrane targeting sequence of the Rho GTPase Lyn (LDR), while CFP-tagged FKBP (FK506- and rapamycin-binding protein) was fused to the N terminus of PKD2 (1-177 or 1-223) to generate CF-PKD2-(177) and CF-PKD2-(223), respectively. Addition of Rap induces rapid heterodimerization between the PM-anchored FRB and FKBP fusion proteins, thus bringing the CF-PKD2 fusions into close proximity of PM-located PKD2 channels.
###end p 42
###begin title 43
DISCUSSION
###end title 43
###begin p 44
###xml 205 214 <span type="species:ncbi:7955">zebrafish</span>
In the present study, we have identified and functionally characterized a new dimerization domain in the N-terminal cytosolic region of PC2. This domain is shown to have a physiologically relevant role in zebrafish development as it phenocopied known loss-of-function constructs of PC2. We propose that the identification of this domain has important implications in type 2 ADPKD pathophysiology.
###end p 44
###begin p 45
###xml 491 495 491 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e.</italic>
###xml 891 895 891 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKD2</italic>
###xml 972 974 972 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
###xml 513 522 <span type="species:ncbi:7955">zebrafish</span>
###xml 905 909 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
The tendency of native PC2 to oligomerize led us initially to investigate how PC2 homodimerization could be regulated. Unexpectedly, we found that two naturally occurring PC2 mutants lacking the C-terminal homodimerization domain (L703X, R742X) could still form oligomers and bind to full-length PC2 in mammalian cells. These findings led us to demonstrate the existence of a more proximal dimerization domain within the N-terminal domain and its functionality in two assays of PC2 activity i.e. nephrogenesis in zebrafish embryos and channel activity in mIMCD3 cells. These findings are compatible with a likely dominant negative effect in both models. Overall, our data would support a direct acute inhibitory effect of the mutant protein (PKD2-L223) on the PC2 channel itself, which also leads to subsequent degradation of PC2. Recently, it was reported that the transgenic expression of PKD2-L703X in rats gave rise to a cystic phenotype by an undetermined mechanism (27). We believe that our findings of an N-terminal dimerization domain support a dominant negative mechanism as a plausible explanation of the phenotype in this model.
###end p 45
###begin p 46
###xml 178 184 178 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7</xref>
###xml 394 395 394 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 458 465 458 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 600 602 600 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref28">28</xref>
###xml 837 841 837 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g.</italic>
###xml 1029 1033 1029 1033 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g.</italic>
###xml 1105 1109 1105 1109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g.</italic>
###xml 1178 1180 1178 1180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 1182 1184 1182 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref29">29</xref>
The existence of both N- and C-terminal dimerization domains in PC2 provide supportive evidence that PC2 is likely to form functional homotetramers, a possible model is shown in Fig. 7. This model does not require the binding of PC1 or that of other TRP subunits (such as TRPC1) both of which have been shown to interact with PC2 via distinct sequences or amino acids in the C-terminal domain (5). The evidence that PC2 homodimers can function independently in vivo is indirect: PC2 can function independently of PC1 at the embryonic node in the determination of LR asymmetry in the axial body plan (28). Nevertheless, an important question is what regulates the assembly of PC2 monomeric subunits into homotetramers or alternatively heterotetramers with PC1 or other TRP subunits. In addition, we do not know if PC2 truncation mutants (e.g. L703X), which retain the putative pore region and which can still dimerize via the N-terminal domain are still functional. In some assays, there is evidence for altered PC2 localization (e.g. increased cell surface expression) and for altered channel properties (e.g. loss of calcium responsiveness, voltage-dependence) of this mutant (12, 29).
###end p 46
###begin p 47
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 6.</label>
###xml 9 78 9 78 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Inhibition of plasma membrane PKD2 channel activity by CF-PKD2-(223).</bold>
###xml 116 117 116 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 140 141 140 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 174 177 174 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rap</italic>
###xml 379 380 379 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 395 396 395 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 542 543 541 542 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 679 685 678 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arrows</italic>
###xml 773 774 772 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 776 777 775 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 779 780 778 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 782 783 781 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 785 786 784 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 792 793 791 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 827 828 826 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 855 856 854 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 886 887 885 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 922 927 921 926 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black</italic>
###xml 939 942 938 941 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 1032 1033 1031 1032 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1066 1067 1065 1066 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1103 1104 1102 1103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 1142 1147 1141 1146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black</italic>
###xml 1159 1162 1158 1161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 1222 1223 1221 1222 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 1225 1226 1224 1225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 9 1234 9 1233 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="48"><bold>Inhibition of plasma membrane PKD2 channel activity by CF-PKD2-(223).</bold> Time-dependent inhibition of native (<italic>A</italic>) or transfected PKD2 (<italic>E</italic>) channel activity by rapamycin (<italic>rap</italic>)-induced translocation of a CFP fusion of the PC2 N terminus (NT2, 1&#8211;223) to the plasma membrane. mIMCD3 cells were transiently transfected with LDR plus CF-PKD2-(177) or CF-PKD2-(223) in the absence (<italic>A</italic>) or presence (<italic>E</italic>) of transfected wild-type mouse PKD2. Translocation of CF-PKD2-(177) or CF-PKD2-(223) to the plasma membrane was induced by the addition of 10 &#956;<sc>m</sc> rapamycin to the bath solution. Current densities at -100 mV were obtained by 100-ms pulses from -60 mV to -100 mV applied every 10 s. <italic>Arrows</italic> indicate time points at which voltage steps were applied to derive I-V curves shown in <italic>B</italic>, <italic>C</italic>, <italic>D</italic>, <italic>F</italic>, <italic>G</italic>, and <italic>H</italic>. I-V curves derived from native (<italic>B</italic>), LDR plus CF-PKD2-(177) (<italic>C</italic>), or LDR plus CF-PKD2-(223) (<italic>D</italic>)-transfected mIMCD3 cells before (<italic>black</italic>) or after (<italic>red</italic>) the addition of rapamycin in the bath solution are shown. I-V curves derived from PKD2 (<italic>F</italic>), PKD2, LDR, and CF-PKD2-(177) (<italic>G</italic>), or PKD2, LDR, and CF-PKD2-(223) (<italic>H</italic>)-co-transfected mIMCD3 cells before (<italic>black</italic>) or after (<italic>red</italic>) the addition of rapamycin to the bath solution are shown. <sup>*</sup>, <italic>p</italic> &lt; 0.05.</p>
###xml 9 1234 9 1233 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="48"><bold>Inhibition of plasma membrane PKD2 channel activity by CF-PKD2-(223).</bold> Time-dependent inhibition of native (<italic>A</italic>) or transfected PKD2 (<italic>E</italic>) channel activity by rapamycin (<italic>rap</italic>)-induced translocation of a CFP fusion of the PC2 N terminus (NT2, 1&#8211;223) to the plasma membrane. mIMCD3 cells were transiently transfected with LDR plus CF-PKD2-(177) or CF-PKD2-(223) in the absence (<italic>A</italic>) or presence (<italic>E</italic>) of transfected wild-type mouse PKD2. Translocation of CF-PKD2-(177) or CF-PKD2-(223) to the plasma membrane was induced by the addition of 10 &#956;<sc>m</sc> rapamycin to the bath solution. Current densities at -100 mV were obtained by 100-ms pulses from -60 mV to -100 mV applied every 10 s. <italic>Arrows</italic> indicate time points at which voltage steps were applied to derive I-V curves shown in <italic>B</italic>, <italic>C</italic>, <italic>D</italic>, <italic>F</italic>, <italic>G</italic>, and <italic>H</italic>. I-V curves derived from native (<italic>B</italic>), LDR plus CF-PKD2-(177) (<italic>C</italic>), or LDR plus CF-PKD2-(223) (<italic>D</italic>)-transfected mIMCD3 cells before (<italic>black</italic>) or after (<italic>red</italic>) the addition of rapamycin in the bath solution are shown. I-V curves derived from PKD2 (<italic>F</italic>), PKD2, LDR, and CF-PKD2-(177) (<italic>G</italic>), or PKD2, LDR, and CF-PKD2-(223) (<italic>H</italic>)-co-transfected mIMCD3 cells before (<italic>black</italic>) or after (<italic>red</italic>) the addition of rapamycin to the bath solution are shown. <sup>*</sup>, <italic>p</italic> &lt; 0.05.</p></caption>
###xml 1234 1234 1233 1233 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0440853210006"/>
###xml 0 1234 0 1233 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig6"><label>FIGURE 6.</label><caption><p textid="48"><bold>Inhibition of plasma membrane PKD2 channel activity by CF-PKD2-(223).</bold> Time-dependent inhibition of native (<italic>A</italic>) or transfected PKD2 (<italic>E</italic>) channel activity by rapamycin (<italic>rap</italic>)-induced translocation of a CFP fusion of the PC2 N terminus (NT2, 1&#8211;223) to the plasma membrane. mIMCD3 cells were transiently transfected with LDR plus CF-PKD2-(177) or CF-PKD2-(223) in the absence (<italic>A</italic>) or presence (<italic>E</italic>) of transfected wild-type mouse PKD2. Translocation of CF-PKD2-(177) or CF-PKD2-(223) to the plasma membrane was induced by the addition of 10 &#956;<sc>m</sc> rapamycin to the bath solution. Current densities at -100 mV were obtained by 100-ms pulses from -60 mV to -100 mV applied every 10 s. <italic>Arrows</italic> indicate time points at which voltage steps were applied to derive I-V curves shown in <italic>B</italic>, <italic>C</italic>, <italic>D</italic>, <italic>F</italic>, <italic>G</italic>, and <italic>H</italic>. I-V curves derived from native (<italic>B</italic>), LDR plus CF-PKD2-(177) (<italic>C</italic>), or LDR plus CF-PKD2-(223) (<italic>D</italic>)-transfected mIMCD3 cells before (<italic>black</italic>) or after (<italic>red</italic>) the addition of rapamycin in the bath solution are shown. I-V curves derived from PKD2 (<italic>F</italic>), PKD2, LDR, and CF-PKD2-(177) (<italic>G</italic>), or PKD2, LDR, and CF-PKD2-(223) (<italic>H</italic>)-co-transfected mIMCD3 cells before (<italic>black</italic>) or after (<italic>red</italic>) the addition of rapamycin to the bath solution are shown. <sup>*</sup>, <italic>p</italic> &lt; 0.05.</p></caption><graphic xlink:href="zbc0440853210006"/></fig>
###xml 423 428 <span type="species:ncbi:10090">mouse</span>
FIGURE 6.Inhibition of plasma membrane PKD2 channel activity by CF-PKD2-(223). Time-dependent inhibition of native (A) or transfected PKD2 (E) channel activity by rapamycin (rap)-induced translocation of a CFP fusion of the PC2 N terminus (NT2, 1-223) to the plasma membrane. mIMCD3 cells were transiently transfected with LDR plus CF-PKD2-(177) or CF-PKD2-(223) in the absence (A) or presence (E) of transfected wild-type mouse PKD2. Translocation of CF-PKD2-(177) or CF-PKD2-(223) to the plasma membrane was induced by the addition of 10 mum rapamycin to the bath solution. Current densities at -100 mV were obtained by 100-ms pulses from -60 mV to -100 mV applied every 10 s. Arrows indicate time points at which voltage steps were applied to derive I-V curves shown in B, C, D, F, G, and H. I-V curves derived from native (B), LDR plus CF-PKD2-(177) (C), or LDR plus CF-PKD2-(223) (D)-transfected mIMCD3 cells before (black) or after (red) the addition of rapamycin in the bath solution are shown. I-V curves derived from PKD2 (F), PKD2, LDR, and CF-PKD2-(177) (G), or PKD2, LDR, and CF-PKD2-(223) (H)-co-transfected mIMCD3 cells before (black) or after (red) the addition of rapamycin to the bath solution are shown. *, p < 0.05.
###end p 47
###begin p 48
###xml 0 69 0 69 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Inhibition of plasma membrane PKD2 channel activity by CF-PKD2-(223).</bold>
###xml 107 108 107 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 131 132 131 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 165 168 165 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rap</italic>
###xml 370 371 370 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 386 387 386 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 533 534 532 533 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 670 676 669 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arrows</italic>
###xml 764 765 763 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 767 768 766 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 770 771 769 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 773 774 772 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 776 777 775 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 783 784 782 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 818 819 817 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 846 847 845 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 877 878 876 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 913 918 912 917 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black</italic>
###xml 930 933 929 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 1023 1024 1022 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1057 1058 1056 1057 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1094 1095 1093 1094 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 1133 1138 1132 1137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black</italic>
###xml 1150 1153 1149 1152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 1213 1214 1212 1213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 1216 1217 1215 1216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 414 419 <span type="species:ncbi:10090">mouse</span>
Inhibition of plasma membrane PKD2 channel activity by CF-PKD2-(223). Time-dependent inhibition of native (A) or transfected PKD2 (E) channel activity by rapamycin (rap)-induced translocation of a CFP fusion of the PC2 N terminus (NT2, 1-223) to the plasma membrane. mIMCD3 cells were transiently transfected with LDR plus CF-PKD2-(177) or CF-PKD2-(223) in the absence (A) or presence (E) of transfected wild-type mouse PKD2. Translocation of CF-PKD2-(177) or CF-PKD2-(223) to the plasma membrane was induced by the addition of 10 mum rapamycin to the bath solution. Current densities at -100 mV were obtained by 100-ms pulses from -60 mV to -100 mV applied every 10 s. Arrows indicate time points at which voltage steps were applied to derive I-V curves shown in B, C, D, F, G, and H. I-V curves derived from native (B), LDR plus CF-PKD2-(177) (C), or LDR plus CF-PKD2-(223) (D)-transfected mIMCD3 cells before (black) or after (red) the addition of rapamycin in the bath solution are shown. I-V curves derived from PKD2 (F), PKD2, LDR, and CF-PKD2-(177) (G), or PKD2, LDR, and CF-PKD2-(223) (H)-co-transfected mIMCD3 cells before (black) or after (red) the addition of rapamycin to the bath solution are shown. *, p < 0.05.
###end p 48
###begin p 49
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 7.</label>
###xml 9 52 9 52 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A tetrameric model of PC2 channel assembly.</bold>
###xml 9 558 9 558 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="50"><bold>A tetrameric model of PC2 channel assembly.</bold> The existence of N- and C-terminal dimerization domains would facilitate the assembly of four PC2 monomers into a homotetramer. By contrast, a mutant PC2 monomer lacking the distal C-terminal dimerization domain (such as L703X) would still be capable of forming dimers via the proximal N-terminal domain: these mutant dimers could be functional. The incorporation of one mutant PC2 monomer with 3 normal PC2 monomers would permit the formation of a tetrameric structure but is likely to be non-functional.</p>
###xml 9 558 9 558 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="50"><bold>A tetrameric model of PC2 channel assembly.</bold> The existence of N- and C-terminal dimerization domains would facilitate the assembly of four PC2 monomers into a homotetramer. By contrast, a mutant PC2 monomer lacking the distal C-terminal dimerization domain (such as L703X) would still be capable of forming dimers via the proximal N-terminal domain: these mutant dimers could be functional. The incorporation of one mutant PC2 monomer with 3 normal PC2 monomers would permit the formation of a tetrameric structure but is likely to be non-functional.</p></caption>
###xml 558 558 558 558 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0440853210007"/>
###xml 0 558 0 558 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig7"><label>FIGURE 7.</label><caption><p textid="50"><bold>A tetrameric model of PC2 channel assembly.</bold> The existence of N- and C-terminal dimerization domains would facilitate the assembly of four PC2 monomers into a homotetramer. By contrast, a mutant PC2 monomer lacking the distal C-terminal dimerization domain (such as L703X) would still be capable of forming dimers via the proximal N-terminal domain: these mutant dimers could be functional. The incorporation of one mutant PC2 monomer with 3 normal PC2 monomers would permit the formation of a tetrameric structure but is likely to be non-functional.</p></caption><graphic xlink:href="zbc0440853210007"/></fig>
FIGURE 7.A tetrameric model of PC2 channel assembly. The existence of N- and C-terminal dimerization domains would facilitate the assembly of four PC2 monomers into a homotetramer. By contrast, a mutant PC2 monomer lacking the distal C-terminal dimerization domain (such as L703X) would still be capable of forming dimers via the proximal N-terminal domain: these mutant dimers could be functional. The incorporation of one mutant PC2 monomer with 3 normal PC2 monomers would permit the formation of a tetrameric structure but is likely to be non-functional.
###end p 49
###begin p 50
###xml 0 43 0 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A tetrameric model of PC2 channel assembly.</bold>
A tetrameric model of PC2 channel assembly. The existence of N- and C-terminal dimerization domains would facilitate the assembly of four PC2 monomers into a homotetramer. By contrast, a mutant PC2 monomer lacking the distal C-terminal dimerization domain (such as L703X) would still be capable of forming dimers via the proximal N-terminal domain: these mutant dimers could be functional. The incorporation of one mutant PC2 monomer with 3 normal PC2 monomers would permit the formation of a tetrameric structure but is likely to be non-functional.
###end p 50
###begin p 51
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref30">30</xref>
###xml 388 394 388 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7</xref>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
###xml 758 766 <span type="species:ncbi:9606">patients</span>
Our results also raise the possibility as to whether cyst formation in PKD2 patients could arise by a dominant-negative mechanism as shown for the D511V mutant in addition to two-hit and haploinsufficiency models (30). If PC2 forms an oligomeric structure, the association of a mutant protein with wild-type subunits would result in the generation of non-functional multimeric complexes (Fig. 7). For a tetrameric model, potentially 15 of 16 possible combinations between mutant and wild-type subunits could be affected. Therefore, although there will be 50% reduction in the wild-type protein, the reduction in function could approximate 100%. This mechanism would only be effective assuming that a stable mutant mRNA transcript and protein are produced in patients at levels that would bind in a stoichiometric fashion to wild-type monomers. Nonetheless, given the lack of specific inhibitors to PC2, the dominant negative strategy we have described could be a useful way to study the function of the endogenous protein in different systems.
###end p 51
###begin p 52
We thank D. J. Moon and Y. Xu for technical assistance, and T. Meyer, I. Drummond, S. Somlo, and D. Markie for kind gifts of reagents. No conflict of interest is declared.
###end p 52
###begin p 53
The abbreviations used are: ADPKD, autosomal dominant polycystic kidney disease; PKC, protein kinase C; PBS, phosphate-buffered saline; TRP, transient receptor potential; HA, hemagglutinin; IP, immunoprecipitation; CFP, cyan fluorescent protein; NT, N terminus; MO, morpholino.
###end p 53
###begin p 54
Personal communication.
###end p 54

